dbACP: A Comprehensive Database of Anti-Cancer Peptides

1785 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00028 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 14.2% inhibition at 10-6 M
dbacp00029 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 19.7% inhibition at 10-5 M
dbacp00030 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 24.9% inhibition at 10-4 M
dbacp00031 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 30.4% inhibition at 10-3 M
dbacp00032 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 10% inhibition at 10-5 M
dbacp00033 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 8.2% inhibition at 10-4 M
dbacp00034 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 36.1% inhibition at 10-3 M
dbacp00035 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 6.5% inhibition at 10-6 M
dbacp00036 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 14% inhibition at 10-5 M
dbacp00037 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.5% inhibition at 10-4 M
dbacp00038 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 14% inhibition at 10-3 M
dbacp00039 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 9.8% inhibition at 10-6 M
dbacp00040 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 1.6% inhibition at 10-5 M
dbacp00041 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 5.4% inhibition at 10-4 M
dbacp00042 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 26.5% inhibition at 10-3 M
dbacp00043 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 12.9% inhibition at 10-6 M
dbacp00044 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 16.5% inhibition at 10-5 M
dbacp00045 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 28.1% inhibition at 10-4 M
dbacp00046 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 58.2% inhibition at 10-3 M
dbacp00047 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 3.5% inhibition at 10-6 M
dbacp00048 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 22.7% inhibition at 10-5 M
dbacp00049 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 18.9% inhibition at 10-4 M
dbacp00050 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 26.4% inhibition at 10-3 M
dbacp00051 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 2.4% inhibition at 10-5 M
dbacp00052 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.5% inhibition at 10-4 M
dbacp00053 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 6.2% inhibition at 10-6 M
dbacp00054 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 6.4% inhibition at 10-5 M
dbacp00055 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 8.2% inhibition at 10-4 M
dbacp00056 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 21.2% inhibition at 10-3 M
dbacp00057 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.5% inhibition at 10-6 M
dbacp00058 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 6.1% inhibition at 10-5 M
dbacp00059 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 3.1% inhibition at 10-4 M
dbacp00060 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 14.8% inhibition at 10-3 M
dbacp00061 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.9% inhibition at 10-5 M
dbacp00062 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.3% inhibition at 10-3 M
dbacp00063 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 4.9% inhibition at 10-6 M
dbacp00064 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 8.9% inhibition at 10-5 M
dbacp00065 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 3.4% inhibition at 10-4 M
dbacp00066 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 20.8% inhibition at 10-3 M
dbacp00067 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 10.5% inhibition at 10-6 M
dbacp00068 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 21.9% inhibition at 10-5 M
dbacp00069 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 11.8% inhibition at 10-4 M
dbacp00070 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 17.9% inhibition at 10-3 M
dbacp00071 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 3.7% inhibition at 10-6 M
dbacp00072 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 16.5% inhibition at 10-5 M
dbacp00073 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.4% inhibition at 10-4 M
dbacp00074 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 14.5% inhibition at 10-3 M
dbacp00075 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 1.1% inhibition at 10-5 M
dbacp00076 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 1.2% inhibition at 10-4 M
dbacp00077 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 17.8% inhibition at 10-3 M
dbacp00078 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 8.5% inhibition at 10-6 M
dbacp00079 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 4.9% inhibition at 10-5 M
dbacp00080 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 1.9% inhibition at 10-4 M
dbacp00081 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 16.2% inhibition at 10-3 M
dbacp00082 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.2% inhibition at 10-6 M
dbacp00083 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 17.1% inhibition at 10-5 M
dbacp00084 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.0% inhibition at 10-4 M
dbacp00085 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 20.5% inhibition at 10-3 M
dbacp00086 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.0% inhibition at 10-6 M
dbacp00087 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.7% inhibition at 10-5 M
dbacp00088 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.7% inhibition at 10-4 M
dbacp00089 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 7.3% inhibition at 10-3 M
dbacp00090 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 0.7% inhibition at 10-6 M
dbacp00091 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 8.3% inhibition at 10-5 M
dbacp00092 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 10.5% inhibition at 10-4 M
dbacp00093 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 21.8% inhibition at 10-3 M
dbacp00094 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 10.7% inhibition at 10-6 M
dbacp00095 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 10.0% inhibition at 10-5 M
dbacp00096 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.7% inhibition at 10-4 M
dbacp00097 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 18.7% inhibition at 10-3 M
dbacp00125 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 2.7% inhibition at 10-6 M
dbacp00126 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 2.0% inhibition at 10-5 M
dbacp00127 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 18.8% inhibition at 10-4 M
dbacp00128 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 26.7% inhibition at 10-3 M
dbacp00129 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.8% inhibition at 10-6 M
dbacp00130 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.3% inhibition at 10-5 M
dbacp00131 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.9% inhibition at 10-4 M
dbacp00132 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.2% inhibition at 10-3 M
dbacp00133 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.6% inhibition at 10-6 M
dbacp00134 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.9% inhibition at 10-5 M
dbacp00135 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 5.9% inhibition at 10-4 M
dbacp00136 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 17.9% inhibition at 10-3 M
dbacp00137 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 5.4% inhibition at 10-6 M
dbacp00138 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 7.4% inhibition at 10-5 M
dbacp00139 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 9.5% inhibition at 10-4 M
dbacp00140 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 15.7% inhibition at 10-3 M
dbacp00141 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.6% inhibition at 10-6 M
dbacp00142 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 20.4% inhibition at 10-5 M
dbacp00143 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 14.4% inhibition at 10-4 M
dbacp00144 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 23.4% inhibition at 10-3 M
dbacp00145 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 2.2% inhibition at 10-6 M
dbacp00146 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 4.2% inhibition at 10-5 M
dbacp00147 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 6.4% inhibition at 10-4 M
dbacp00148 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 6.2% inhibition at 10-3 M
dbacp00149 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 21.2% inhibition at 10-3 M
dbacp00159 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 4.6% inhibition at 10-6 M
dbacp00160 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 4.9% inhibition at 10-5 M
dbacp00161 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 12.6% inhibition at 10-4 M
dbacp00162 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 26.4% inhibition at 10-3 M
dbacp00163 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.0% inhibition at 10-6 M
dbacp00164 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.7% inhibition at 10-5 M
dbacp00165 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.6% inhibition at 10-4 M
dbacp00166 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.2% inhibition at 10-3 M
dbacp00167 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.2% inhibition at 10-5 M
dbacp00168 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 3.3% inhibition at 10-4 M
dbacp00169 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 19.4% inhibition at 10-3 M
dbacp00170 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 7.6% inhibition at 10-6 M
dbacp00171 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 3.8% inhibition at 10-5 M
dbacp00172 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 12.4% inhibition at 10-4 M
dbacp00173 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 22.4% inhibition at 10-3 M
dbacp00174 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 17.0% inhibition at 10-6 M
dbacp00175 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.5% inhibition at 10-5 M
dbacp00176 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.5% inhibition at 10-4 M
dbacp00177 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 25.3% inhibition at 10-3 M
dbacp00178 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.1% inhibition at 10-6 M
dbacp00179 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 6.9% inhibition at 10-5 M
dbacp00180 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.1% inhibition at 10-4 M
dbacp00181 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.6% inhibition at 10-3 M
dbacp00182 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 15.6% inhibition at 10-3 M
dbacp00192 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 1.0% inhibition at 10-6 M
dbacp00193 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 10.1% inhibition at 10-5 M
dbacp00194 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 16.8% inhibition at 10-4 M
dbacp00195 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 36.1% inhibition at 10-3 M
dbacp00196 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 4.9% inhibition at 10-6 M
dbacp00197 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 10.2% inhibition at 10-5 M
dbacp00198 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 13.3% inhibition at 10-4 M
dbacp00199 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.0% inhibition at 10-3 M
dbacp00200 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 0.8% inhibition at 10-6 M
dbacp00201 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 1.4% inhibition at 10-5 M
dbacp00202 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.4% inhibition at 10-4 M
dbacp00203 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 18.3% inhibition at 10-3 M
dbacp00204 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 3.3% inhibition at 10-6 M
dbacp00205 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 11.0% inhibition at 10-5M
dbacp00206 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 7.9% inhibition at 10-4 M
dbacp00207 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 23.7% inhibition at 10-3 M
dbacp00208 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 12.2% inhibition at 10-6 M
dbacp00209 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 15.5% inhibition at 10-5 M
dbacp00210 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 24.7% inhibition at 10-4 M
dbacp00211 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 29.0% inhibition at 10-3 M
dbacp00212 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 3.0% inhibition at 10-6 M
dbacp00213 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.4% inhibition at 10-5 M
dbacp00214 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 18.5% inhibition at 10-4 M
dbacp00215 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 10.6% inhibition at 10-3 M
dbacp00216 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 22.8% inhibition at 10-3 M
dbacp00226 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 13.7% inhibition at 10-6 M
dbacp00227 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 25.8% inhibition at 10-5 M
dbacp00228 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 34.7% inhibition at 10-4 M
dbacp00229 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 44.5% inhibition at 10-3 M
dbacp00230 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 8.5% inhibition at 10-6 M
dbacp00231 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.5% inhibition at 10-5 M
dbacp00232 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 15.4% inhibition at 10-4 M
dbacp00233 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 24.1% inhibition at 10-3 M
dbacp00234 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 2.4% inhibition at 10-6 M
dbacp00235 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.5% inhibition at 10-5 M
dbacp00236 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 11.4% inhibition at 10-4 M
dbacp00237 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 23.2% inhibition at 10-3 M
dbacp00238 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 16.2% inhibition at 10-6 M
dbacp00239 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 6.6% inhibition at 10-5 M
dbacp00240 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 5.1% inhibition at 10-4 M
dbacp00241 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 14.5% inhibition at 10-3 M
dbacp00242 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 26.4% inhibition at 10-6 M
dbacp00243 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 13.1% inhibition at 10-5 M
dbacp00244 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 14.6% inhibition at 10-4 M
dbacp00245 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay SW-620 Colon cancer 38.4% inhibition at 10-3 M
dbacp00246 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 17.7% inhibition at 10-6 M
dbacp00247 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 10.9% inhibition at 10-5 M
dbacp00248 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 12.1% inhibition at 10-4 M
dbacp00249 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 8.1% inhibition at 10-3 M
dbacp00250 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 9.6% inhibition at 10-4 M
dbacp00251 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 29.9% inhibition at 10-3 M
dbacp00279 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 3.9% inhibition at 10-5 M
dbacp00280 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HEp-2 Larynx cancer 45% inhibition at 10-3 M
dbacp00281 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.3% inhibition at 10-3 M
dbacp00282 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 4.1% inhibition at 10-6 M
dbacp00283 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 70.7% inhibition at 10-5 M
dbacp00284 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HBL Skin cancer 34.4% inhibition at 10-3 M
dbacp00285 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HT-29 Colon cancer 9.2% inhibition at 10-3 M
dbacp00286 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 11.08% inhibition at 10-5 M
dbacp00287 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay CaCo-2 Colon cancer 47.0% inhibition at 10-3 M
dbacp00288 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 2.2% inhibition at 10-6 M
dbacp00289 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.1% inhibition at 10-5 M
dbacp00290 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 6.9% inhibition at 10-4 M
dbacp00291 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 25.9% inhibition at 10-3 M
dbacp00570 [L9]-P18 KWKLFKKILKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 3 µM
dbacp00571 [L9]-P18 KWKLFKKILKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 9 µM
dbacp00572 [L9]-P18 KWKLFKKILKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 3 µM
dbacp00618 [S9]-P18 KWKLFKKISKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 4 µM
dbacp00619 [S9]-P18 KWKLFKKISKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 7 µM
dbacp00620 [S9]-P18 KWKLFKKISKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 3 µM
dbacp00704 10a NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 28 µM
dbacp00705 10b NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 11.4 µM
dbacp00706 10c NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 6.6 µM
dbacp00707 11a NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 5.2 µM
dbacp00708 11b NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 19 µM
dbacp00709 11c NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 7.2 µM
dbacp00710 12a NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 6.1 µM
dbacp00711 12b NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 27 µM
dbacp00712 12c NA Synthetic b2,2-amino acid derivatives Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 14 µM
dbacp00722 5a NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 10.6 µM
dbacp00723 5b NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 7.1 µM
dbacp00724 5c NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 4.1 µM
dbacp00727 6a NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 14.4 µM
dbacp00728 6b NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 11.0 µM
dbacp00729 6c NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 4.3 µM
dbacp00730 7a NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : >63 µM
dbacp00731 7b NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : >78 µM
dbacp00732 7c NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 79 µM
dbacp00733 8a NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 136 µM
dbacp00734 8b NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : >254 µM
dbacp00735 8c NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 107 µM
dbacp00736 9a NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 31 µM
dbacp00737 9b NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 2.3 µM
dbacp00738 9c NA Not found Induction of apoptosis; Disruption of cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 3.1 µM
dbacp00739 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay LNCaP Prostate cancer IC50 : 44 µM
dbacp00740 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay LNCaP Prostate cancer IC50 : 23 µM
dbacp00741 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay LNCaP Prostate cancer IC50 : 28 µM
dbacp00742 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 39 µM
dbacp00743 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 29 µM
dbacp00744 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 16 µM
dbacp00745 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 93 µM
dbacp00746 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 39 µM
dbacp00747 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 37 µM
dbacp00748 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 36 µM
dbacp00749 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 25 µM
dbacp00750 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay J774A.1 Tumor IC50 : 47 µM
dbacp00751 9R RRRRRNWMWC Not found Cell membrane disintegration; Apoptosis MTT/MTS assay J774A.1 Tumor IC50 : 12 µM
dbacp00752 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay LNCaP Prostate cancer IC50 : 26 µM
dbacp00753 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay LNCaP Prostate cancer IC50 : 9 µM
dbacp00754 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay LNCaP Prostate cancer IC50 : 8 µM
dbacp00755 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 18 µM
dbacp00756 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 12 µM
dbacp00757 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 10 µM
dbacp00758 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 38 µM
dbacp00759 9S1R RRRRRWCMNW Not found Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 43 µM
dbacp00760 9S1R RRRRRWCMNW Nullomer derived anticancer peptides (NulloPs) Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 43 µM
dbacp00761 9S1R RRRRRWCMNW Nullomer derived anticancer peptides (NulloPs) Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 45 µM
dbacp00762 9S1R RRRRRWCMNW Nullomer derived anticancer peptides (NulloPs) Cell membrane disintegration; Apoptosis MTT/MTS assay HUT-102 Lymphoma cancer IC50 : 36 µM
dbacp00763 9S1R RRRRRWCMNW Nullomer derived anticancer peptides (NulloPs) Cell membrane disintegration; Apoptosis MTT/MTS assay J774A.1 Tumor IC50 : 26 µM
dbacp00764 9S1R RRRRRWCMNW Nullomer derived anticancer peptides (NulloPs) Cell membrane disintegration; Apoptosis MTT/MTS assay J774A.1 Tumor IC50 : 17 µM
dbacp00773 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 11.1 µMo/L
dbacp00774 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 4.3 µMo/L
dbacp00775 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 5 µMo/L
dbacp00776 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : 6.4 µMo/L
dbacp00777 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : 7.5 µMo/L
dbacp00778 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : 4.4 µMo/L
dbacp00779 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 5.2 µMo/L
dbacp00780 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 3.8 µMo/L
dbacp00781 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 9.7 µMo/L
dbacp00782 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 8.7 µMo/L
dbacp00783 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 6.2 µMo/L
dbacp00784 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : 4.3 µMo/L
dbacp00785 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : 6.4 µMo/L
dbacp00786 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : 4.1 µMo/L
dbacp00787 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 4.4 µMo/L
dbacp00788 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2 µMo/L
dbacp00789 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 9.2 µMo/L
dbacp00790 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 7.2 µMo/L
dbacp00791 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 5.7 µMo/L
dbacp00792 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : 3.5 µMo/L
dbacp00793 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : 5.5 µMo/L
dbacp00794 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : 2.7 µMo/L
dbacp00795 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 4.6 µMo/L
dbacp00796 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.2 µMo/L
dbacp00797 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 8.7 µMo/L
dbacp00798 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 6.5 µMo/L
dbacp00799 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 5.1 µMo/L
dbacp00800 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : 5 µMo/L
dbacp00801 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : 9.8 µMo/L
dbacp00802 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : 2.9 µMo/L
dbacp00803 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 7.8 µMo/L
dbacp00804 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 4.3 µMo/L
dbacp00813 A5 KAQIRAMECNIL Cyclin B (285-296) Apoptosis inducing MTT/MTS assay HCT-116 Colon cancer Not found
dbacp00814 AAD (or Aa-Pri1) MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYPSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYWECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN Purified from chestnut mushroom Apoptosis inducing MTT/MTS assay HepG-2 Liver cancer At 2.5 µM concentration,decrease in cell vibility: 35%
dbacp00815 AAD (or Aa-Pri1) MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYPSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYWECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN Purified from chestnut mushroom Apoptosis inducing MTT/MTS assay HeLa Cervical cancer At 2.5 µM concentration,decrease in cell vibility: 70%
dbacp00816 AAD (or Aa-Pri1) MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYPSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYWECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN Purified from chestnut mushroom Apoptosis inducing MTT/MTS assay SH-SY5Y Brain tumor At 2.5 µM concentration,decrease in cell vibility: 70%
dbacp01174 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 50% inhibition at 2.5 µg/ml
dbacp01175 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 40% inhibition at 5 µg/ml
dbacp01176 AP ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 75% inhibition at 10 µg/ml
dbacp01177 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 40% inhibition at 2.5 µg/ml
dbacp01178 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 42% inhibition at 5 µg/ml
dbacp01179 AP(O) ACDCRGDCFCGGGGIVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Antiangiogenesis MTT/MTS assay BAE Tumor 52% inhibition at 10 µg/ml
dbacp01180 Apo E LRVRLASHLRKLRKRLLRDADDLQKRLAVY Apoprotein E Cell membrane disintegration MTT/MTS assay PANC-1 Pancreatic cancer 55 % Cytotoxity at 40 µg/ml
dbacp01181 Apo E LRVRLASHLRKLRKRLLRDADDLQKRLAVY Apoprotein E Cell membrane disintegration MTT/MTS assay Paca-2 Pancreatic cancer 55 % Cytotoxity at 40 µg/ml
dbacp01182 Apo E LRVRLASHLRKLRKRLLRDADDLQKRLAVY Apoprotein E Cell membrane disintegration MTT/MTS assay MKN-1 Gastric cancer 60 % Cytotoxity at 40 µg/ml
dbacp01183 Apo E LRVRLASHLRKLRKRLLRDADDLQKRLAVY Apoprotein E Cell membrane disintegration MTT/MTS assay MKN-7 Gastric cancer 35 % Cytotoxity at 40 µg/ml
dbacp01184 Apo E LRVRLASHLRKLRKRLLRDADDLQKRLAVY Apoprotein E Cell membrane disintegration MTT/MTS assay COLO-201 Colon cancer 65 % Cytotoxity at 40 µg/ml
dbacp01440 BAA-1 NA Bovine lactoferrin (Lf-B) Destabilizing the cell membrane MTT/MTS assay Ramos Lymphoma cancer IC50 : 8.1 µg/ml
dbacp01441 BAA-2 NA Bovine lactoferrin (Lf-B) Apoptosis inducing MTT/MTS assay Ramos Lymphoma cancer IC50 : 3.8 µg/ml
dbacp01598 BF2d TRSSRAGLQWPVGRVHRLLRKGGC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 1 µM 90-100% viablity
dbacp01599 BF2d TRSSRAGLQWPVGRVHRLLRKGGC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 10 µM 90-95% viablity
dbacp01600 BF2d TRSSRAGLQWPVGRVHRLLRKGGC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 100 µM 90-100% viablity
dbacp01916 BPP-II MTLTG Immunomodulatory bursal-derived Pentapeptide-II Inducing apoptosis MTT/MTS assay CEF Tumor Not found
dbacp01917 BPP-II MTLTG Immunomodulatory bursal-derived Pentapeptide-II Inducing apoptosis MTT/MTS assay Vero Renal cancer Not found
dbacp01918 BPP-II MTLTG Immunomodulatory bursal-derived Pentapeptide-II Inducing apoptosis MTT/MTS assay MDBK Renal cancer Not found
dbacp01987 Buforin 2 TRSSRAGLQFPVGRVHRLLRK Asiatic toad Disruption of electric potential of the cell membrane; Necrosis, Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer IC50 : 90-95 µg/ml
dbacp01989 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 14.7 µg/ml
dbacp01990 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay HL-60 Leukemia cancer IC50 : 11.3 µg/ml
dbacp01991 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay K-562 Leukemia cancer IC50 : 8.2 µg/ml
dbacp01992 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay MOLT-4 Leukemia cancer IC50 : 17 µg/ml
dbacp01993 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay RPMI-8226 Leukemia cancer IC50 : 10.5 µg/ml
dbacp01994 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SR Leukemia cancer IC50 : 20.2 µg/ml
dbacp01995 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 15.1 µg/ml
dbacp01996 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay NCI/ADR-RES Breast cancer IC50 : 11.5 µg/ml
dbacp01997 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay MDA-MB-231 Breast cancer IC50 : 11.3 µg/ml
dbacp01998 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay HS578T Breast cancer IC50 : 11.7 µg/ml
dbacp01999 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay MDA-MB-435 Breast cancer IC50 : 11.3 µg/ml
dbacp02000 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay MDA-N Breast cancer IC50 : 10.6 µg/ml
dbacp02001 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay BT-549 Breast cancer IC50 : 12.9 µg/ml
dbacp02002 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay T-47D Breast cancer IC50 : 23.9 µg/ml
dbacp02003 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 11.7 µg/ml
dbacp02004 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay EKVX Lung cancer IC50 : 12.1 µg/ml
dbacp02005 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay HOP-62 Lung cancer IC50 : 12.6 µg/ml
dbacp02006 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay HOP-92 Lung cancer IC50 : 7.2 µg/ml
dbacp02007 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay NCI-H226 Lung cancer IC50 : 13.3 µg/ml
dbacp02008 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay NCI-H23 Lung cancer IC50 : 10.8 µg/ml
dbacp02009 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay NCI-H322M Lung cancer IC50 : 10.7 µg/ml
dbacp02010 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay NCI-H460 Lung cancer IC50 : 12.1 µg/ml
dbacp02011 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay NCI-H522 Lung cancer IC50 : 11.2 µg/ml
dbacp02012 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SF-268 Brain tumor IC50 : 12.4 µg/ml
dbacp02013 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SF-295 Brain tumor IC50 : 12.9 µg/ml
dbacp02014 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SF-539 Brain tumor IC50 : 9.5 µg/ml
dbacp02015 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SNB-19 Brain tumor IC50 : 13.8 µg/ml
dbacp02016 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SNB-75 Brain tumor IC50 : 15.5 µg/ml
dbacp02017 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay U-251 Brain tumor IC50 : 10.6 µg/ml
dbacp02018 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay LOXIMVI Skin cancer IC50 : 9.5 µg/ml
dbacp02019 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay MALME-3M Skin cancer IC50 : 10.9 µg/ml
dbacp02020 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay M14 Skin cancer IC50 : 15.1 µg/ml
dbacp02021 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 11.1 µg/ml
dbacp02022 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SK-MEL-5 Skin cancer IC50 : 8.9 µg/ml
dbacp02023 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay UACC-257 Skin cancer IC50 : 12.5 µg/ml
dbacp02024 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay UACC-62 Skin cancer IC50 : 10.6 µg/ml
dbacp02025 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay 786-0 Renal cancer IC50 : 12.2 µg/ml
dbacp02026 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay A-498 Renal cancer IC50 : 10 µg/ml
dbacp02027 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay ACHN Renal cancer IC50 : 12 µg/ml
dbacp02028 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay CAKI-1 Renal cancer IC50 : 14.1 µg/ml
dbacp02029 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay RFX393 Renal cancer IC50 : 11 µg/ml
dbacp02030 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SN-12C Renal cancer IC50 : 11.4 µg/ml
dbacp02031 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay TK-10 Renal cancer IC50 : 13.1 µg/ml
dbacp02032 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay UO-31 Renal cancer IC50 : 10.6 µg/ml
dbacp02033 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay IGROV1 Ovarian cancer IC50 : 9 µg/ml
dbacp02034 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay OVRCAR-3 Ovarian cancer IC50 : 15.2 µg/ml
dbacp02035 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay OVRCAR-4 Ovarian cancer IC50 : 17.6 µg/ml
dbacp02036 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay OVRCAR-5 Ovarian cancer IC50 : 13.8 µg/ml
dbacp02037 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay OVRCAR-8 Ovarian cancer IC50 : 13 µg/ml
dbacp02038 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SK-OV-3 Ovarian cancer IC50 : 12.6 µg/ml
dbacp02039 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay COLO-205 Colon cancer IC50 : 11.2 µg/ml
dbacp02040 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay HCT-116 Colon cancer IC50 : 14.6 µg/ml
dbacp02041 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay HCT-15 Colon cancer IC50 : 13.2 µg/ml
dbacp02042 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay HT-29 Colon cancer IC50 : 17.6 µg/ml
dbacp02043 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay KM12 Colon cancer IC50 : 12 µg/ml
dbacp02044 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay SW-620 Colon cancer IC50 : 12.7 µg/ml
dbacp02045 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay PC-3 Prostate cancer IC50 : 12 µg/ml
dbacp02046 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay DU-145 Prostate cancer IC50 : 15.3 µg/ml
dbacp02047 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay CCRF-CEM Not specified IC50 : 14.7 µg/ml
dbacp02048 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay HL-60 Not specified IC50 : 11.3 µg/ml
dbacp02049 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay K562 Not specified IC50 : 8.2 µg/ml
dbacp02050 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay MOLT4 Not specified IC50 : 17.0 µg/ml
dbacp02051 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay RPMI-8226 Not specified IC50 : 10.5 µg/ml
dbacp02052 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SR Not specified IC50 : 20.2 µg/ml
dbacp02053 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay MCF-7 Not specified IC50 : 15.1 µg/ml
dbacp02054 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay NCI/ADR-RES Not specified IC50 : 11.5 µg/ml
dbacp02055 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay MDA-MB-231 Not specified IC50 : 11.3 µg/ml
dbacp02056 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay HS 578T Not specified IC50 : 11.7 µg/ml
dbacp02057 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay MDA-MB-435 Not specified IC50 : 11.3 µg/ml
dbacp02058 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay MDA-N Not specified IC50 : 10.6 µg/ml
dbacp02059 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay BT-549 Not specified IC50 : 12.9 µg/ml
dbacp02060 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay T-47D Not specified IC50 : 23.9 µg/ml
dbacp02061 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay A549 Not specified IC50 : 11.7 µg/ml
dbacp02062 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay EKVX Not specified IC50 : 12.1 µg/ml
dbacp02063 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay HOP-62 Not specified IC50 : 12.6 µg/ml
dbacp02064 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay HOP-92 Not specified IC50 : 7.2 µg/ml
dbacp02065 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay NCI-H226 Not specified IC50 : 13.3µg/ml
dbacp02066 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay NCI-H23 Not specified IC50 : 10.8 µg/ml
dbacp02067 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay NCI-H322M Not specified IC50 : 10.7 µg/ml
dbacp02068 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay NCI-H460 Not specified IC50 : 12.1 µg/ml
dbacp02069 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay NCI-H522 Not specified IC50 : 11.2 µg/ml
dbacp02070 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SF-268 Not specified IC50 : 12.4 µg/ml
dbacp02071 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SF-295 Not specified IC50 : 12.9 µg/ml
dbacp02072 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SF-539 Not specified IC50 : 9.5 µg/ml
dbacp02073 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SNB-19 Not specified IC50 : 13.8 µg/ml
dbacp02074 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SNB-75 Not specified IC50 : 15.5 µg/ml
dbacp02075 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay U251 Not specified IC50 : 10.6 µg/ml
dbacp02076 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay LOX IMVI Not specified IC50 : 9.5 µg/ml
dbacp02077 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay MALME-3M Not specified IC50 : 10.9 µg/ml
dbacp02078 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay M14 Not specified IC50 : 15.1 µg/ml
dbacp02079 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SK-MEL-2 Not specified IC50 : 11.1 µg/ml
dbacp02080 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SK-MEL-5 Not specified IC50 : 8.9 µg/ml
dbacp02081 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay UACC-257 Not specified IC50 : 12.5µg/ml
dbacp02082 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay UACC-62 Not specified IC50 : 10.6 µg/ml
dbacp02083 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay 786-0 Not specified IC50 : 12.2 µg/ml
dbacp02084 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay A498 Not specified IC50 : 10 µg/ml
dbacp02085 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay ACHN Not specified IC50 : 12 µg/ml
dbacp02086 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay CAKI-1 Not specified IC50 : 14.1 µg/ml
dbacp02087 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay RFX 393 Not specified IC50 : 11 µg/ml
dbacp02088 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SN12C Not specified IC50 : 11.1 µg/ml
dbacp02089 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay TK-10 Not specified IC50 : 13.1 µg/ml
dbacp02090 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay UO-31 Not specified IC50 : 10.6 µg/ml
dbacp02091 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay IGROV 1 Not specified IC50 : 9 µg/ml
dbacp02092 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay OVRCAR-3 Not specified IC50 : 15.2 µg/ml
dbacp02093 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay OVRCAR-4 Not specified IC50 : 17.6 µg/ml
dbacp02094 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay OVRCAR-5 Not specified IC50 : 13.8 µg/ml
dbacp02095 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay OVRCAR-8 Not specified IC50 : 13 µg/ml
dbacp02096 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SKOV3 Not specified IC50 : 12.6 µg/ml
dbacp02097 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay COLO-205 Not specified IC50 : 11.2 µg/ml
dbacp02098 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay HCT116 Not specified IC50 : 14.6 µg/ml
dbacp02099 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay HT-29 Not specified IC50 : 13.2 µg/ml
dbacp02100 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay HCT-15 Not specified IC50 : 12 µg/ml
dbacp02101 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay KM12 Not specified IC50 : 12 µg/ml
dbacp02102 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay SW-620 Not specified IC50 : 12.7 µg/ml
dbacp02103 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay HCT-15 Not specified IC50 : 17.6 µg/ml
dbacp02104 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay DU-145 Not specified IC50 : 15.3 µg/ml
dbacp02105 Buforin2 TRSSRAGLQFPVGRVHRLLRK Asiatic toad Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 5% Cytotoxicity at 0.5 µg/ml
dbacp02113 C-1 KWKLFKKIPFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 26 µM
dbacp02114 C-1 KWKLFKKIPFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 32 µM
dbacp02115 C-1 KWKLFKKIPFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 31 µM
dbacp02116 C-10 KWKLFKKIPKFLH Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : <100 µM
dbacp02117 C-10 KWKLFKKIPKFLH Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : <100 µM
dbacp02118 C-10 KWKLFKKIPKFLH Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : <100 µM
dbacp02119 C-2 KWKLFKKIPKFLHLAKK Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 38 µM
dbacp02120 C-2 KWKLFKKIPKFLHLAKK Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 26 µM
dbacp02121 C-2 KWKLFKKIPKFLHLAKK Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 23 µM
dbacp02122 C-3 KWKLFKKIPLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 79 µM
dbacp02123 C-3 KWKLFKKIPLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 74 µM
dbacp02124 C-3 KWKLFKKIPLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 62 µM
dbacp02125 C-4 KWKLFKKIPKFLHLAK Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 54 µM
dbacp02126 C-4 KWKLFKKIPKFLHLAK Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 31 µM
dbacp02127 C-4 KWKLFKKIPKFLHLAK Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 25 µM
dbacp02128 C-5 KWKLFKKIPHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 100 µM
dbacp02129 C-5 KWKLFKKIPHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 81 µM
dbacp02130 C-5 KWKLFKKIPHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 67 µM
dbacp02131 C-6 KWKLFKKIPKFLHLA Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 47 µM
dbacp02132 C-6 KWKLFKKIPKFLHLA Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 21 µM
dbacp02133 C-6 KWKLFKKIPKFLHLA Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 27 µM
dbacp02134 C-7 KWKLFKKIPLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : <100 µM
dbacp02135 C-7 KWKLFKKIPLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : <100 µM
dbacp02136 C-7 KWKLFKKIPLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : <100 µM
dbacp02137 C-8 KWKLFKKIPKFLHL Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 83 µM
dbacp02138 C-8 KWKLFKKIPKFLHL Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 54 µM
dbacp02139 C-8 KWKLFKKIPKFLHL Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 30 µM
dbacp02140 C-9 KWKLFKKIPLKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : <100 µM
dbacp02141 C-9 KWKLFKKIPLKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : <100 µM
dbacp02142 C-9 KWKLFKKIPLKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : <100 µM
dbacp02145 C1 KKWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 10 ±2 µMol/L
dbacp02146 C1 KKWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 22 ±5 µMol/L
dbacp02148 C2 KWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 7.9 ± 0.3 µMol/L
dbacp02149 C2 KWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 1.71 ± 0.6 µMol/L
dbacp02150 C3 KKβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 15 ± 2 µMol/L
dbacp02151 C3 KKβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 92 ± 2 µMol/L
dbacp02152 C4 KWβ2,2KK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 12.6 ± 0.6 µMol/L
dbacp02153 C4 KWβ2,2KK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 99 ± 15 µMol/L
dbacp02154 C5 KKWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 11 ± 2 µMol/L
dbacp02155 C5 KKWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 23 ± 3 µMol/L
dbacp02156 C6 KWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 8 ± 1 µMol/L
dbacp02157 C6 KWβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 26 ± 2 µMol/L
dbacp02158 C7 KKβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 16 ± 5 µMol/L
dbacp02159 C7 KKβ2,2WKK Synthetic construct Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 157 ± 30 µMol/L
dbacp02160 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :10.6 ± 0.4 µM
dbacp02161 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :13.0 ± 1.0 µM
dbacp02162 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :12.1 ± 1.6 µM
dbacp02163 C7A KILRGVAKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :37 ± 4.3 µM
dbacp02164 C7A KILRGVAKKILRTFLRRISKDILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 10.6 ± 0.4 µM
dbacp02165 C7A KILRGVAKKILRTFLRRISKDILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.0 ± 1.0 µM
dbacp02166 C7A KILRGVAKKILRTFLRRISKDILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.1 ± 1.6 µM
dbacp02167 C7A KILRGVAKKILRTFLRRISKDILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 3.7 ± 4.3 µM
dbacp02181 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.4 ± 0.2 µM
dbacp02182 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 2.0 µM
dbacp02183 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.3 ± 0.5 µM
dbacp02184 C7A-D21K KILRGVAKKIMRTFLRRISKKILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 1.0 µM
dbacp02185 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.4 ± 0.2 µM
dbacp02186 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 2.0 µM
dbacp02187 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 8.3 ± 0.5 µM
dbacp02188 C7A-D21k KILRGVAKKIMRTFLRRISKKILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 12.3 ± 1.0 µM
dbacp02202 C7A-Δ KILRGVAKKIMRTFLRRILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 7.5 ± 0.4 µM
dbacp02203 C7A-Δ KILRGVAKKIMRTFLRRILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.8 ± 2.0 µM
dbacp02204 C7A-Δ KILRGVAKKIMRTFLRRILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 9.3 ± 1.5 µM
dbacp02205 C7A-Δ KILRGVAKKIMRTFLRRILTGKK NK-2 variants Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.1 ± 0.9 µM
dbacp02206 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.8 ± 2.0 µM
dbacp02207 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 9.3 ± 1.5 µM
dbacp02208 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 13.1 ± 0.9 µM
dbacp02222 C7A-Δ KILRGVAKKIMRTFLRRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 7.5 ± 0.4 µM
dbacp02223 C8 KWβ2,2KK Not found Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 20 ± 2 µMol/L
dbacp02224 C8 KWβ2,2KK Not found Membrane disruptive mode of action MTT/MTS assay Ramos Lymphoma cancer IC50 : 226 ± 21 µMol/L
dbacp02225 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-Melittin hybrid Membrane disruptive mode of action MTT/MTS assay Calu-6 Lung cancer Activity : ~90% survival rate at 10 µM
dbacp02226 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-Melittin hybrid Membrane disruptive mode of action MTT/MTS assay Calu-6 Lung cancer Activity : <20% survival rate at 100 µM
dbacp02227 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-Melittin hybrid Membrane disruptive mode of action MTT/MTS assay Jurkat Blood cancer Activity : 100% survival rate at 10 µM
dbacp02228 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-Melittin hybrid Membrane disruptive mode of action MTT/MTS assay Jurkat Blood cancer Activity : 0% survival rate at 100 µM
dbacp02229 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-Melittin hybrid Membrane disruptive mode of action MTT/MTS assay SNU-601 Gastric cancer Activity : ~80% survival rate at 10 µM
dbacp02230 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-Melittin hybrid Membrane disruptive mode of action MTT/MTS assay SNU-601 Gastric cancer Activity : 10% survival rate at 100 µM
dbacp02231 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 65 µM
dbacp02232 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 60 µM
dbacp02233 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 30 µM
dbacp02234 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 44 µM
dbacp02235 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin A-African clawed frog Apoptosis MTT/MTS assay NCI-H69 Lung cancer IC50 : 15.8 µM
dbacp02236 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin A-African clawed frog Apoptosis MTT/MTS assay NCI-H128 Lung cancer IC50 : 16.1 µM
dbacp02237 CA-MA KWKLFKKIGIGKFLHSAKKF Ceropin A-African clawed frog Apoptosis MTT/MTS assay NCI-H146 Lung cancer IC50 : 15.8 µM
dbacp02238 CA-MA-P KWKLFKKIPKFLHSAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 20 µM
dbacp02239 CA-MA-P KWKLFKKIPKFLHSAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 20 µM
dbacp02240 CA-MA-P KWKLFKKIPKFLHSAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 25 µM
dbacp02241 CA-MA1 KWKLFKKIKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 85.3 µM
dbacp02242 CA-MA1 KWKLFKKIKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 100 µM
dbacp02243 CA-MA1 KWKLFKKIKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 65 µM
dbacp02244 CA-MA1 KWKLFKKIKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 100 µM
dbacp02245 CA-MA2 KWKLFKKIPKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 35.1 µM
dbacp02246 CA-MA2 KWKLFKKIPKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 25 µM
dbacp02247 CA-MA2 KWKLFKKIPKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 20 µM
dbacp02248 CA-MA2 KWKLFKKIPKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 28 µM
dbacp02249 CA-MA3 KWKLFKKIGPGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : >100 µM
dbacp02250 CA-MA3 KWKLFKKIGPGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : >100 µM
dbacp02251 CA-MA3 KWKLFKKIGPGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 75 µM
dbacp02252 CA-MA3 KWKLFKKIGPGKFLHSAKKF Ceropin-African clawed frog hybrid peptides Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : >100 µM
dbacp02253 CA-ME KWKLFKKIGIGAVLKVLTTG Ceropin A-African clawed frog Apoptosis MTT/MTS assay NCI-H69 Lung cancer IC50 : 32.2 µM
dbacp02254 CA-ME KWKLFKKIGIGAVLKVLTTG Ceropin A-African clawed frog Apoptosis MTT/MTS assay NCI-H128 Lung cancer IC50 : 28.6 µM
dbacp02255 CA-ME KWKLFKKIGIGAVLKVLTTG Ceropin A-African clawed frog Apoptosis MTT/MTS assay NCI-H146 Lung cancer IC50 : 28.6 µM
dbacp02270 Camel KWKLFKKIGAVLKVL Ceropin-Melittin hybrid Cell swelling and rupture of the plasma membrane MTT/MTS assay B16-F10 Skin cancer LC50 : 1.75 µM
dbacp02271 Camel KWKLFKKIGAVLKVL Ceropin-Melittin hybrid Cell swelling and rupture of the plasma membrane MTT/MTS assay RENCA Renal cancer LC50 : 1.3 µM
dbacp02272 Camel KWKLFKKIGAVLKVL Ceropin-Melittin hybrid Cell swelling and rupture of the plasma membrane MTT/MTS assay 4T1 Breast cancer LC50 : 6.2 µM
dbacp02273 Camel KWKLFKKIGAVLKVL Ceropin-Melittin hybrid Cell swelling and rupture of the plasma membrane MTT/MTS assay WM1158 Skin cancer LC50 : 4.1 µM
dbacp02305 Caseinphosphopeptides PPPEE Bovine milk Regulation of immune response; Apoptosis inducing MTT/MTS assay AZ-97 Colon cancer Inhibition at 24-28g/l
dbacp02306 Caspase 3 inhibitor DEVD Caspase 3 inhibitor Cell membrane disruption MTT/MTS assay Bcap-37 Breast cancer 65% cytotoxicity at 20 µM approx.
dbacp02307 Caspase 3 inhibitor DEVD Caspase 3 inhibitor Cell membrane disruption MTT/MTS assay Bcap-37 Breast cancer 65% cytotoxicity at 30 µM
dbacp02308 Caspase 3 inhibitor DEVD Caspase 3 inhibitor Cell membrane disruption MTT/MTS assay Bcap-37 Breast cancer 65% cytotoxicity at 40 µM
dbacp02338 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis MTT/MTS assay SCC12 Skin cancer IC50 : 1 µM
dbacp02339 Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK Isolated from the giant silk moth, cecropia moth Membrane damage; Apoptotic cell death; Necrosis MTT/MTS assay SCC25 Skin cancer IC50 : 2.2 µM
dbacp02483 Chrysophsin-1 FFGWLIKGAIHAGKAIHGLI The pyloric caeca and gills; Red sea bream Disruption of cancer cell membranes; Apoptosis MTS assay, Lactate dehydrogenase (LDH) detection assay HT-1080 Human fibrosarcoma MIC : 7 µg/ml
dbacp02484 Chrysophsin-1 FFGWLIKGAIHAGKAIHGLI The pyloric caeca and gills; Red sea bream Disruption of cancer cell membranes; Apoptosis MTS assay, Lactate dehydrogenase (LDH) detection assay U937 Histiocytic lymphoma MIC : 7 µg/ml
dbacp02485 Chrysophsin-1 FFGWLIKGAIHAGKAIHGLI The pyloric caeca and gills; Red sea bream Disruption of cancer cell membranes; Apoptosis MTS assay, Lactate dehydrogenase (LDH) detection assay HeLa Epithelial carcinoma MIC : 7 µg/ml
dbacp02487 Citropin 1.1 GLFDVIKKVASVIGGL Australian blue mountains tree frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-938 Lymphoma cancer IC50 :40 µg/ml
dbacp02512 Citropin1.1 GLFDVIKKVASVIGGL Australian blue mountains tree frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 60% Cytotoxicity at 0.5 µg/ml
dbacp02513 Citropin1.1 GLFDVIKKVASVIGGL Australian blue mountains tree frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 60% Cytotoxicity at 0.5 µg/ml
dbacp02594 Cyclic [W(RW)4 ]-Dox WRWRWRWRW Not found Inhibition of the cell proliferation MTT/MTS assay CCRF-CEM Leukemia cancer 62-73% inhibition of cell proliferation at 1 µM
dbacp02595 Cyclic [W(RW)4 ]-Dox WRWRWRWRW Not found Inhibition of the cell proliferation MTT/MTS assay SK-OV-3 Ovarian cancer 51-74% inhibition of cell proliferation at 1 µM
dbacp02596 Cyclic [W(RW)4 ]-Dox WRWRWRWRW Not found Inhibition of the cell proliferation MTT/MTS assay HCT-116 Colon cancer 50-67% inhibition of cell proliferation at 1 µM
dbacp02597 Cyclic [W(RW)4 ]-Dox WRWRWRWRW Not found Inhibition of the cell proliferation MTT/MTS assay MDA-MB-468 Breast cancer 60-79% inhibition of cell proliferation at 1 µM
dbacp02627 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer IC50 : 3.2 ± 0.6 µM
dbacp02628 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay KB Oral cancer IC50 : 4.5 ± 0.5 µM
dbacp02629 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : 4.7 ± 0.4 µM
dbacp02630 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay MDA-MB-436 Breast cancer IC50 : 3.2 ± 0.4 µM
dbacp02646 Demegen P-113 AKRHHGYKRKFH Thrush Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-939 Lymphoma cancer IC50 : 85-90 µg/ml
dbacp02647 Demegen P-113 AKRHHGYKRKFH Amphibian skin peptide Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 15% Cytotoxicity at 0.5 µg/ml
dbacp02744 Dex-(KW)3 KWKWKW Synthetic Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer At 10 µM 60% viablity
dbacp02745 Dex-(KW)3 KWKWKW Synthetic Cell membrane disruption MTT/MTS assay MCF-7 Breast cancer At 10 µM 35-40% viablity
dbacp02748 Di-PST13-RK-C KKKFPWWWPFKKKCKKKFPWWWPFKKKC Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 17 µg/ml
dbacp02749 Di-PST13-RK-C KKKFPWWWPFKKKCKKKFPWWWPFKKKC Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 17 µg/ml
dbacp02750 Di-PST13-RK-K KKKFPWWWPFKKKKKKFPWWWPFKKKK Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 15 µg/ml
dbacp02751 Di-PST13-RK-K KKKFPWWWPFKKKKKKFPWWWPFKKKK Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 10 µg/ml
dbacp02757 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 1.31 nM
dbacp02758 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay DU Prostate cancer IC50 : 2.85 nM
dbacp02759 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 0.62 nM
dbacp02783 dLL-37(17-32)c FKRiVQRiKDFlRNLV LL-37, a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Tumor Not found
dbacp02784 dLL-37(17-32)c FKRIVQRIKDFLRNLV LL-37, a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Oral cancer Not found
dbacp02785 dLL-37(17-32)c FKRIVQRIKDFLRNLV LL-37, a series of peptide fragments Cell membrane disintegration MTT/MTS assay HBMEC Prostate cancer Not found
dbacp02810 DP1 KLAKLAKKLAKLAK Protein transduction domain Induction of apoptosis MTT/MTS assay MCA205 Renal cancer LC50 : < 50 µM
dbacp02811 DP1 KLAKLAKKLAKLAK KLA sequence repeats, motif-based design Induction of apoptosis MTT/MTS assay MCA205 Renal cancer LC50 : < 50 µM
dbacp02828 EGFR-related peptide ERRP EGFR-related peptide Apoptosis MTT/MTS assay PC-3 Prostate cancer 30% Cell viability at 5 µg/ml
dbacp02843 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 45% Cytotoxicity at 50 mg/L
dbacp02844 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 38% Cytotoxicity at 25 mg/L
dbacp02845 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75% Cytotoxicity at 50 mg/L
dbacp02846 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 65% Cytotoxicity at 25 mg/L
dbacp02847 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75 % Cytotoxicity at 50 mg/L
dbacp02848 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 65% Cytotoxicity at 25 mg/L
dbacp02849 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 83% Cytotoxicity at 50 mg/L
dbacp02850 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 77 % Cytotoxicity at 25 mg/L
dbacp02851 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 82 % Cytotoxicity at 50 mg/L
dbacp02852 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 85 % Cytotoxicity at 25 mg/L
dbacp02853 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 42 % Cytotoxicity at 12.5 mg/L
dbacp02854 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 41 % Cytotoxicity at 6.25 mg/L
dbacp02855 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 39 % Cytotoxicity at 3.125 mg/L
dbacp02856 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 90 % Cytotoxicity at 50 mg/L
dbacp02857 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 95 % Cytotoxicity at 25 mg/L
dbacp02858 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 45 % Cytotoxicity at 12.5 mg/L
dbacp02859 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 25 % Cytotoxicity at 6.25 mg/L
dbacp02860 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 25 % Cytotoxicity at 3.125 mg/L
dbacp02861 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 95 % Cytotoxicity at 50 mg/L
dbacp02862 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 96 % Cytotoxicity at 25 mg/L
dbacp02863 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 46 % Cytotoxicity at 12.5 mg/L
dbacp02864 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 30 % Cytotoxicity at 6.25 mg/L
dbacp02865 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 28 % Cytotoxicity at 3.125 mg/L
dbacp02866 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 84 % Cytotoxicity at 50 mg/L
dbacp02867 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 85 % Cytotoxicity at 25 mg/L
dbacp02868 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 38 % Cytotoxicity at 12.5 mg/L
dbacp02869 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 30 % Cytotoxicity at 6.25 mg/L
dbacp02870 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 28 % Cytotoxicity at 3.125 mg/L
dbacp02874 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 60 % Cytotoxicity at 50 mg/L
dbacp02875 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 50 % Cytotoxicity at 25 mg/L
dbacp02876 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 8 % Cytotoxicity at 12.5 mg/L
dbacp02877 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 6.25 mg/L
dbacp02878 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 3.125 mg/L
dbacp02879 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75 % Cytotoxicity at 50 mg/L
dbacp02880 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp02881 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 12.5 mg/L
dbacp02882 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 7 % Cytotoxicity at 6.25 mg/L
dbacp02883 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 3.125 mg/L
dbacp02884 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 76 % Cytotoxicity at 50 mg/L
dbacp02885 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp02886 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 12 % Cytotoxicity at 12.5 mg/L
dbacp02887 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 6.25 mg/L
dbacp02888 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 3.125 mg/L
dbacp02889 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 90 % Cytotoxicity at 50 mg/L
dbacp02890 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75 % Cytotoxicity at 25 mg/L
dbacp02891 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 8 % Cytotoxicity at 12.5 mg/L
dbacp02892 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 3 % Cytotoxicity at 6.25 mg/L
dbacp02893 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 3 % Cytotoxicity at 3.125 mg/L
dbacp02894 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 60 % Cytotoxicity at 50 mg/L
dbacp02895 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 50 % Cytotoxicity at 25 mg/L
dbacp02896 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 8 % Cytotoxicity at 12.5 mg/L
dbacp02897 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 10 % Cytotoxicity at 6.25 mg/L
dbacp02898 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 5 % Cytotoxicity at 3.125 mg/L
dbacp02899 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 75 % Cytotoxicity at 50 mg/L
dbacp02900 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 70 % Cytotoxicity at 25 mg/L
dbacp02901 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 5 %Cytotoxicity at 12.5 mg/L
dbacp02902 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 7 % Cytotoxicity at 6.25 mg/L
dbacp02903 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 10 % Cytotoxicity at 3.125 mg/L
dbacp02904 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 76 % Cytotoxicity at 50 mg/L
dbacp02905 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 70 % Cytotoxicity at 25 mg/L
dbacp02906 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 12 % Cytotoxicity at 12.5 mg/L
dbacp02907 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 4 % Cytotoxicity at 6.25 mg/L
dbacp02908 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 4 % Cytotoxicity at 3.125 mg/L
dbacp02909 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 90 % Cytotoxicity at 50 mg/L
dbacp02910 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 75 % Cytotoxicity at 25 mg/L
dbacp02911 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 8 % Cytotoxicity at 12.5 mg/L
dbacp02912 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 3 % Cytotoxicity at 6.25 mg/L
dbacp02913 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 3 % Cytotoxicity at 3.125 mg/L
dbacp02914 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 2.5µg/ml
dbacp02915 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 5µg/ml
dbacp02916 ES-2 IVRRADRAAVP Endostatin derived synthetic peptide Necrosis; Anti-angiogenesis MTT/MTS assay BAE Tumor 60% inhibition at 10µg/ml
dbacp02972 GA-K3 FLGWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-498 Renal cancer IC50 : 41.21 µM
dbacp02973 GA-K3 FLGWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 25.20 µM
dbacp02974 GA-K3 FLGWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay HCT-116 Colon cancer IC50 : 27.00 µM
dbacp02975 GA-K3 FLGWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay MKN-45 Gastric cancer IC50 : 26.70 µM
dbacp02976 GA-K3 FLGWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer IC50 : 47.69 µM
dbacp02977 GA-K3 FLGWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 27.39 µM
dbacp02978 GA-K3 FLGWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-OV-3 Ovarian cancer IC50 : 27.39 µM
dbacp02979 GA-K3 FLGWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-498 Renal cancer IC50 : 41.21 µM
dbacp02980 GA-K3 FLGWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 25.20 µM
dbacp02981 GA-K3 FLGWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay HCT-116 Colon cancer IC50 : 27.00 µM
dbacp02982 GA-K3 FLGWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay MKN-45 Gastric cancer IC50 : 26.70 µM
dbacp02983 GA-K3 FLGWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer IC50 : 47.69 µM
dbacp02984 GA-K3 FLGWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 27.39 µM
dbacp02985 GA-K3 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-OV-3 Ovarian cancer IC50 : 24.76 µM
dbacp02986 GA-K4 FLKWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-498 Renal cancer IC50 : 21.48 µM
dbacp02987 GA-K4 FLKWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 14.53 µM
dbacp02988 GA-K4 FLKWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay HCT-116 Colon cancer IC50 : 14.80 µM
dbacp02989 GA-K4 FLKWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay MKN-45 Gastric cancer IC50 : 22.51 µM
dbacp02990 GA-K4 FLKWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer IC50 :29.10 µM
dbacp02991 GA-K4 FLKWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 :22.25 µM
dbacp02992 GA-K4 FLKWLFKWAKK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-OV-3 Ovarian cancer IC50 :12.55 µM
dbacp02993 GA-K4 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-498 Renal cancer IC50 : 21.48 µM
dbacp02994 GA-K4 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 14.53 µM
dbacp02995 GA-K4 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay HCT-116 Colon cancer IC50 : 14.8 µM
dbacp02996 GA-K4 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay MKN-45 Gastric cancer IC50 : 22.51 µM
dbacp02997 GA-K4 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer IC50 : 29.10 µM
dbacp02998 GA-K4 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 22.25 µM
dbacp02999 GA-K4 FLKWLFKWAKK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-OV-3 Ovarian cancer IC50 : 12.55 µM
dbacp03000 GA-W3 FLGWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-498 Renal cancer IC50 : 22.88 µM
dbacp03001 GA-W3 FLGWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 20.36 µM
dbacp03002 GA-W3 FLGWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay HCT-116 Colon cancer IC50 : 24.63 µM
dbacp03003 GA-W3 FLGWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay MKN-45 Gastric cancer IC50 : 24.31 µM
dbacp03004 GA-W3 FLGWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer IC50 : 46.51 µM
dbacp03005 GA-W3 FLGWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 13.97 µM
dbacp03006 GA-W3 FLGWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-OV-3 Ovarian cancer IC50 : 22.06 µM
dbacp03007 GA-W3 FLGWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-498 Renal cancer IC50 : 22.88 µM
dbacp03008 GA-W3 FLGWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 20.36 µM
dbacp03009 GA-W3 FLGWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay HCT-116 Colon cancer IC50 : 24.63 µM
dbacp03010 GA-W3 FLGWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay MKN-45 Gastric cancer IC50 : 24.31 µM
dbacp03011 GA-W3 FLGWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer IC50 : 46.51 µM
dbacp03012 GA-W3 FLGWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 13.97 µM
dbacp03013 GA-W3 FLGWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-OV-3 Ovarian cancer IC50 : 22.06 µM
dbacp03014 GA-W4 FLWWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-498 Renal cancer IC50 :22.59 µM
dbacp03015 GA-W4 FLWWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 15.88 µM
dbacp03016 GA-W4 FLWWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay HCT-116 Colon cancer IC50 : 14.80 µM
dbacp03017 GA-W4 FLWWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay MKN-45 Gastric cancer IC50 : 13.77 µM
dbacp03018 GA-W4 FLWWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer IC50 : 24.32 µM
dbacp03019 GA-W4 FLWWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 13.16 µM
dbacp03020 GA-W4 FLWWLFKWAWK Undecapeptide analogues derived from Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-OV-3 Ovarian cancer IC50 : 14.58 µM
dbacp03021 GA-W4 FLWWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-498 Renal cancer IC50 : 22.59 µM
dbacp03022 GA-W4 FLWWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay A-549 Lung cancer IC50 : 15.88 µM
dbacp03023 GA-W4 FLWWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay HCT-116 Colon cancer IC50 : 14.80 µM
dbacp03024 GA-W4 FLWWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay MKN-45 Gastric cancer IC50 : 13.77 µM
dbacp03025 GA-W4 FLWWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay PC-3 Prostate cancer IC50 : 24.32 µM
dbacp03026 GA-W4 FLWWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-MEL-2 Skin cancer IC50 : 13.16 µM
dbacp03027 GA-W4 FLWWLFKWAWK Brevinin-1EMa Cell membrane disruption MTT/MTS assay SK-OV-3 Ovarian cancer IC50 : 14.58 µM
dbacp03057 GGN6 FLPLLAGLAANFLPTIICKISYKC Skin of a Korean frog, wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 6.49 µg/ml
dbacp03058 GGN6 FLPLLAGLAANFLPTIICKISYKC Skin of a Korean frog, wrinkled frog Induce apoptosis MTT/MTS assay HEK293 Renal cancer IC50 : 5.62 µg/ml
dbacp03059 GGN6 FLPLLAGLAANFLPTIICKISYKC Skin of a Korean frog, wrinkled frog Induce apoptosis MTT/MTS assay HEK301 Renal cancer IC50 : 5.75 µg/ml
dbacp03060 GGN6 FLPLLAGLAANFLPTIICKISYKC Skin of a Korean frog, wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 4.91 µg/ml
dbacp03061 GGN6 FLPLLAGLAANFLPTIICKISYKC Skin of a Korean frog, wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 4.88 µg/ml
dbacp03189 HAL-1 GMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 11 ± 2 µM
dbacp03190 HAL-1 GMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 44 ± 8 µM
dbacp03191 HAL-1 GMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 49 ± 9 µM
dbacp03192 HAL-1/10 GMWKKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 13 ± 2 µM
dbacp03193 HAL-1/10 GMWKKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 60 µM
dbacp03194 HAL-1/10 GMWKKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03195 HAL-1/12 GKWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 43 ± 14 µM
dbacp03196 HAL-1/12 GKWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp03197 HAL-1/12 GKWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : > 40 µM
dbacp03198 HAL-1/15 GMWSKLLGHLLR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 14 ± 2 µM
dbacp03199 HAL-1/15 GMWSKLLGHLLR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp03200 HAL-1/15 GMWSKLLGHLLR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : > 40 µM
dbacp03201 HAL-1/17 KMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 35 ± 3 µM
dbacp03202 HAL-1/17 KMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp03203 HAL-1/17 KMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03204 HAL-1/18 GMWSKILKHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 4 ± 2 µM
dbacp03205 HAL-1/18 GMWSKILKHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 18 ± 2 µM
dbacp03206 HAL-1/18 GMWSKILKHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03207 HAL-1/19 GKWKKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 100 µM
dbacp03208 HAL-1/19 GKWKKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp03209 HAL-1/19 GKWKKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03210 HAL-1/20 GKWSKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 22 ± 3 µM
dbacp03211 HAL-1/20 GKWSKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp03212 HAL-1/20 GKWSKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : > 40 µM
dbacp03213 HAL-1/21 GKWKKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 30 ± 3 µM
dbacp03214 HAL-1/21 GKWKKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp03215 HAL-1/21 GKWKKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03216 HAL-1/22 gmwskilghlir Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ±3 µM
dbacp03217 HAL-1/22 gmwskilghlir Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp03218 HAL-1/22 gmwskilghlir Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03219 HAL-1/29 GMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 100 µM
dbacp03220 HAL-1/29 GMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp03221 HAL-1/29 GMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03222 HAL-1/4 GMWSKILGHLKR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 100 µM
dbacp03223 HAL-1/4 GMWSKILGHLKR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp03224 HAL-1/4 GMWSKILGHLKR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03225 HAL-1/5 GMWKKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 1 µM
dbacp03226 HAL-1/5 GMWKKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 44 ± 5 µM
dbacp03227 HAL-1/5 GMWKKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : > 40 µM
dbacp03228 HAL-1/6 GMWSKILGHLIK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ± 1 µM
dbacp03229 HAL-1/6 GMWSKILGHLIK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp03230 HAL-1/6 GMWSKILGHLIK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03231 HAL-1/9 GMWSKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 1 µM
dbacp03232 HAL-1/9 GMWSKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 50 µM
dbacp03233 HAL-1/9 GMWSKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 30 ± 10 µM
dbacp03234 HAL-2 GKWMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 12 ± 1 µM
dbacp03235 HAL-2 GKWMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 35 ± 3 µM
dbacp03236 HAL-2 GKWMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 34 µM
dbacp03237 HAL-2/1 GKWKSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 14 ± 2 µM
dbacp03238 HAL-2/1 GKWKSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp03239 HAL-2/1 GKWKSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : > 40 µM
dbacp03240 HAL-2/11 GKWLSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 14 ± 3 µM
dbacp03241 HAL-2/11 GKWLSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 40 µM
dbacp03242 HAL-2/11 GKWLSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03243 HAL-2/13 GKWMTLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 13 ± 3 µM
dbacp03244 HAL-2/13 GKWMTLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 60 µM
dbacp03245 HAL-2/13 GKWMTLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03246 HAL-2/18 GKWMSLLKHIWK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 14 ± 2 µM
dbacp03247 HAL-2/18 GKWMSLLKHIWK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp03248 HAL-2/18 GKWMSLLKHIWK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03249 HAL-2/19 GKWMSLLKHWLK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 16 ± 4 µM
dbacp03250 HAL-2/19 GKWMSLLKHWLK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp03251 HAL-2/19 GKWMSLLKHWLK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03252 HAL-2/2 GKWMKLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 6 ± 1 µM
dbacp03253 HAL-2/2 GKWMKLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 35 ± 5 µM
dbacp03254 HAL-2/2 GKWMKLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : > 40 µM
dbacp03255 HAL-2/20 GKWMSLWKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 30 ± 5 µM
dbacp03256 HAL-2/20 GKWMSLWKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp03257 HAL-2/20 GKWMSLWKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03258 HAL-2/22 gkwmsllkhilk Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 12 µM
dbacp03259 HAL-2/22 gkwmsllkhilk Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp03260 HAL-2/22 gkwmsllkhilk Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03261 HAL-2/24 GKFMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 34 µM
dbacp03262 HAL-2/24 GKFMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp03263 HAL-2/24 GKFMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03264 HAL-2/4 GKWMSLLKKILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 40 µM
dbacp03265 HAL-2/4 GKWMSLLKKILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 38 ± 6 µM
dbacp03266 HAL-2/4 GKWMSLLKKILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03267 HAL-2/6 GKWMSFLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 23 ± 3 µM
dbacp03268 HAL-2/6 GKWMSFLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp03269 HAL-2/6 GKWMSFLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03270 HAL-2/8 GKWMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ± 3 µM
dbacp03271 HAL-2/8 GKWMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp03272 HAL-2/8 GKWMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp03279 Harmoniasin IGGYCSELDL-NH Harlequin lady beetle Induce apoptotic and necrotic cell deaths MTS assay and LDH release assay U937 Human leukemia MIC : approx. 200 µg/ml
dbacp03280 Harmoniasin IGGYCSELDL-NH Harlequin lady beetle Induce apoptotic and necrotic cell deaths MTS assay and LDH release assay Jurkat Human leukemia MIC : approx. 200 µg/ml
dbacp03366 IbACP AASTPVGGGRRLDRGQ Sweet potato leaves Apoptosis MTT/MTS assay H1299 Lung cancer MIC : 5 mg/ml
dbacp03529 KW5 KAAKKAAKAAKKAAKAAKKAA Bovine lactoferrin (Lf-B) Through interactions with the plasma membrane MTT/MTS assay FEMX Skin cancer IC50 : 30 ± 3 µM
dbacp03530 KW5 KAAKKAAKAAKKAAKAAKKAA Synthetic peptide Through interactions with the plasma membrane MTT/MTS assay HT-29 Colon cancer IC50 : 55 ± 14 µM
dbacp03549 L1 PEWFKCRRWQWRMKKLGA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : > 404 µM
dbacp03550 L1 PEWFKCRRWQWRMKKLGA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : > 404 µM
dbacp03551 L1 PEWFKCRRWQWRMKKLGA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : > 404 µM
dbacp03552 L10 PAARKAFRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 24 µM
dbacp03553 L10 PAARKAFRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 20 µM
dbacp03554 L10 PAARKAFRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 35 µM
dbacp03555 L11 PAARKAARWAWRMLKKGA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 116 µM
dbacp03556 L11 PAARKAARWAWRMLKKGA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 75 µM
dbacp03557 L11 PAARKAARWAWRMLKKGA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 248 µM
dbacp03558 L12 PAWRKAFRWAKRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 7.9 µM
dbacp03559 L12 PAWRKAFRWAKRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 10 µM
dbacp03560 L12 PAWRKAFRWAKRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 25 µM
dbacp03561 L13 PAWRKAFRKAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 14 µM
dbacp03562 L13 PAWRKAFRKAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 12 µM
dbacp03563 L13 PAWRKAFRKAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 29 µM
dbacp03564 L14 PAWRKARRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 125 µM
dbacp03565 L14 PAWRKARRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 141 µM
dbacp03566 L14 PAWRKARRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 423 µM
dbacp03567 L15 PAWRKARRWARRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 87 µM
dbacp03568 L15 PAWRKARRWARRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 92 µM
dbacp03569 L15 PAWRKARRWARRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 178 µM
dbacp03570 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : > 83.6 µMo/L
dbacp03571 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : > 83.6 µMo/L
dbacp03572 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : > 83.6 µMo/L
dbacp03573 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : > 83.6 µMo/L
dbacp03574 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : > 83.6 µMo/L
dbacp03575 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : 16.4 µMo/L
dbacp03576 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : > 83.6 µMo/L
dbacp03577 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : > 83.6 µMo/L
dbacp03578 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : > 83.6 µMo/L
dbacp03579 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : > 83.6 µMo/L
dbacp03580 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : > 83.6 µMo/L
dbacp03581 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : > 83.6 µMo/L
dbacp03582 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : > 83.6 µMo/L
dbacp03583 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : 37.7 µMo/L
dbacp03584 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : >83.6 µMo/L
dbacp03585 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : >83.6 µMo/L
dbacp03586 L2 PAWFKARRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 144 µM
dbacp03587 L2 PAWFKARRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : >254 µM
dbacp03588 L2 PAWFKARRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : >440 µM
dbacp03589 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 71 µMo/L
dbacp03590 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 59.8 µMo/L
dbacp03591 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 70.8 µMo/L
dbacp03592 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : >83.6 µMo/L
dbacp03593 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : >83.6 µMo/L
dbacp03594 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : 15.6 µMo/L
dbacp03595 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 63.5 µMo/L
dbacp03596 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 64.7 µMo/L
dbacp03597 L3 PAWRKAFRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 32 µM
dbacp03598 L3 PAWRKAFRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 18 µM
dbacp03599 L3 PAWRKAFRWAWRMKKLAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 141 µM
dbacp03604 L4 PAWFKARRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 31 µM
dbacp03605 L4 PAWFKARRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 16 µM
dbacp03606 L4 PAWFKARRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 57 µM
dbacp03607 L5 PAWRKAFRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 6.6 µM
dbacp03608 L5 PAWRKAFRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 8 µM
dbacp03609 L5 PAWRKAFRWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 14 µM
dbacp03610 L6 PAWRKAFRWAARMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 11 µM
dbacp03611 L6 PAWRKAFRWAARMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 12 µM
dbacp03612 L6 PAWRKAFRWAARMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 15 µM
dbacp03613 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 53 µMo/L
dbacp03614 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 58.7 µMo/L
dbacp03615 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 62.3 µMo/L
dbacp03616 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : >83.6 µMo/L
dbacp03617 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : >83.6 µMo/L
dbacp03618 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : 14 µMo/L
dbacp03619 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 62.5 µMo/L
dbacp03620 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 58.6 µMo/L
dbacp03621 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : >83.6 µMo/L
dbacp03622 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : >83.6 µMo/L
dbacp03623 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : >83.6 µMo/L
dbacp03624 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : >83.6 µMo/L
dbacp03625 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : >83.6 µMo/L
dbacp03626 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : >83.6 µMo/L
dbacp03627 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : >83.6 µMo/L
dbacp03628 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : >83.6 µMo/L
dbacp03629 L7 PAWRKAFRAAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 16 µM
dbacp03630 L7 PAWRKAFRAAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 11 µM
dbacp03631 L7 PAWRKAFRAAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 16 µM
dbacp03632 L8 PAWAKAFRAAARMKLKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 110 µM
dbacp03633 L8 PAWAKAFRAAARMKLKAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 87 µM
dbacp03634 L8 PAWAKAFRAAARMKLKAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 180 µM
dbacp03635 L9 PAWRKAARWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay Meth A Skin cancer IC50 : 35 µM
dbacp03636 L9 PAWRKAARWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 :32 µM
dbacp03637 L9 PAWRKAARWAWRMLKKAA Lactoferrin Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 52 µM
dbacp03638 Lactoferricin B FKCRRWQWRMKKLGA Temporins family Inducing mitochondria-dependent apoptosis MTT/MTS assay Kelly Brain tumor IC50 : 15.5 µM
dbacp03639 Lactoferricin B FKCRRWQWRMKKLGA Temporins family Inducing mitochondria-dependent apoptosis MTT/MTS assay IMR-32 Brain tumor IC50 : 29 µM
dbacp03640 Lactoferricin B FKCRRWQWRMKKLGA Temporins family Inducing mitochondria-dependent apoptosis MTT/MTS assay SK-N-DZ Brain tumor IC50 : 37 µM
dbacp03641 Lactoferricin B FKCRRWQWRMKKLGA Temporins family Inducing mitochondria-dependent apoptosis MTT/MTS assay SHEP-12 Brain tumor IC50 : 45 µM
dbacp03642 Lactoferricin B FKCRRWQWRMKKLGA Temporins family Inducing mitochondria-dependent apoptosis MTT/MTS assay SH-SY-5Y2 Brain tumor IC50 : 60 µM
dbacp03729 LfcinB FKCRRWQWRMKK Bovine milk Regulation of immune response; Apoptosis MTT/MTS assay AZ-97 Colon cancer Inhibition at 0.1g/l
dbacp03730 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay HT-29 Colon cancer IC50 : > 160 µM
dbacp03731 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay MT-1 Breast cancer IC50 : > 160 µM
dbacp03732 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay Kelly Brain tumor IC50 : 141 ± 3 µM
dbacp03733 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay FEMX Skin cancer IC50 : 40 ± 7 µM
dbacp03734 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay HT-29 Colon cancer IC50 : 148 ± 8 µM
dbacp03735 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay KMS-5 Skin cancer IC50 : 38 µM
dbacp03736 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay U-266 Lymphoma cancer IC50 : 55 µM
dbacp03737 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay KMM-1 Skin cancer IC50 : 57 µM
dbacp03738 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay Sudhl-4 Skin cancer IC50 : 16 µM
dbacp03739 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay Raji Lymphoma cancer IC50 : 13 µM
dbacp03740 LfcinB FKCRRWQWRMKK Bovine lactoferrin (Lf-B) Cell membrane disintegration; Regulation of immune response; Apoptosis MTT/MTS assay Ramos Lymphoma cancer IC50 : 10 µM
dbacp04103 linear (RW)4-Dox RWRWRWRW Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP Inhibition of the cell proliferation MTT/MTS assay CCRF-CEM Leukemia cancer 46-69% anti-proliferative activity at 1 µM
dbacp04104 linear (RW)4-Dox RWRWRWRW Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP Inhibition of the cell proliferation MTT/MTS assay SK-OV-3 Ovarian cancer 28-34% anti-proliferative activity at 1 µM
dbacp04105 linear (RW)4-Dox RWRWRWRW Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP Inhibition of the cell proliferation MTT/MTS assay HCT-116 Colon cancer 21-61% anti-proliferative activity at 1 µM
dbacp04106 linear (RW)4-Dox RWRWRWRW Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP Inhibition of the cell proliferation MTT/MTS assay MDA-MB-468 Breast cancer 60-74% anti-proliferative activity at 1 µM
dbacp04128 LK-L1C/K6W/L8C CKKLLWLCKKLLKLAG Not found Inducing apoptosis MTS assay HeLa Not specified Not found
dbacp04129 LK-L1C/K6W/L8C CKKLLWLCKKLLKLAG Not found Inducing apoptosis MTS assay MCF-7 Not specified Not found
dbacp04148 LL 37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Also known human cathelicidin Plasma membrane perturbations MTT/MTS assay MCF-7 Breast cancer LC50 : 21 at 100 µM
dbacp04149 LL 37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Also known human cathelicidin Plasma membrane perturbations MTT/MTS assay LNCaP Prostate cancer LC50 : 27 at 100 µM
dbacp04150 LL 37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Also known human cathelicidin Plasma membrane perturbations MTT/MTS assay OVRCAR-3 Ovarian cancer LC50 : 24 at 100 µM
dbacp04155 LL-37(1-12) LLGDFFRKSKEK LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Tumor Not found
dbacp04156 LL-37(1-12) LLGDFFRKSKEK LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Oral cancer Not found
dbacp04157 LL-37(1-12) LLGDFFRKSKEK LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay HBMEC Prostate cancer Not found
dbacp04158 LL-37(1-4,17-27) LLGDFKRIVQRIKDF LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Tumor Not found
dbacp04159 LL-37(1-4,17-27) LLGDFKRIVQRIKDF LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Oral cancer Not found
dbacp04160 LL-37(1-4,17-27) LLGDFKRIVQRIKDF LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay HBMEC Prostate cancer Not found
dbacp04161 LL-37(13-37) IGKEFKRIVQRIKDFLRNLVPRTES LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Tumor LC50 : 39 µM
dbacp04162 LL-37(13-37) IGKEFKRIVQRIKDFLRNLVPRTES LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Oral cancer LC50 : 40 µM
dbacp04163 LL-37(13-37) IGKEFKRIVQRIKDFLRNLVPRTES LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay HBMEC Prostate cancer LC50 : 38 µM
dbacp04167 LL-37(17-29) FKRIVQRIKDFLR LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Tumor LC50 : 60 µM
dbacp04168 LL-37(17-29) FKRIVQRIKDFLR LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Oral cancer LC50 : 57 µM
dbacp04169 LL-37(17-29) FKRIVQRIKDFLR LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay HBMEC Prostate cancer LC50 : 55 µM
dbacp04177 LL-37(17-32)b FKRIVQRIKDFLRNLV LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Tumor LC50 : 30 µM
dbacp04178 LL-37(17-32)b FKRIVQRIKDFLRNLV LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay KBv Oral cancer LC50 : 30 µM
dbacp04179 LL-37(17-32)b FKRIVQRIKDFLRNLV LL-37,a series of peptide fragments Cell membrane disintegration MTT/MTS assay HBMEC Prostate cancer LC50 : 25 µM
dbacp04180 LL-III VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 4 ± 1 µM
dbacp04181 LL-III VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 18 ±4 µM
dbacp04182 LL-III VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 5 ± 3 µM
dbacp04183 LL-III/1 VNWKKILAKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 ± 1 µM
dbacp04184 LL-III/1 VNWKKILAKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 12 ± 3 µM
dbacp04185 LL-III/1 VNWKKILAKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 3 ± 1 µM
dbacp04186 LL-III/10 KNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 4 µM
dbacp04187 LL-III/10 KNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp04188 LL-III/10 KNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 9 µM
dbacp04189 LL-III/11 VNWKKIILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 1 µM
dbacp04190 LL-III/11 VNWKKIILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 48 µM
dbacp04191 LL-III/11 VNWKKIILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 4 ± 1 µM
dbacp04192 LL-III/12 vnwkkilgkiikvvk Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 6 ± 2 µM
dbacp04193 LL-III/12 vnwkkilgkiikvvk Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 20 µM
dbacp04194 LL-III/12 vnwkkilgkiikvvk Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 5 ± 2 µM
dbacp04195 LL-III/15 VNFKKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 7 ± 1 µM
dbacp04196 LL-III/15 VNFKKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 42 µM
dbacp04197 LL-III/15 VNFKKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 9 ± 3 µM
dbacp04198 LL-III/16 VN-NAl-KKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 6 ± 1 µM
dbacp04199 LL-III/16 VN-NAl-KKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp04200 LL-III/16 VN-NAl-KKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp04201 LL-III/17 VNWRRILGRIIRVVR Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 µM
dbacp04202 LL-III/17 VNWRRILGRIIRVVR Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp04203 LL-III/17 VNWRRILGRIIRVVR Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp04204 LL-III/18 KNWKKILKKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 µM
dbacp04205 LL-III/18 KNWKKILKKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp04206 LL-III/18 KNWKKILKKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 7 ± 2 µM
dbacp04207 LL-III/19 VNWKK-Aib-LGK-Aib-IK-Aib-VK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 ± 1 µM
dbacp04208 LL-III/19 VNWKK-Aib-LGK-Aib-IK-Aib-VK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 28 µM
dbacp04209 LL-III/19 VNWKK-Aib-LGK-Aib-IK-Aib-VK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 8 ± 2 µM
dbacp04210 LL-III/2 NVWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer Not found
dbacp04211 LL-III/2 NVWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 11 µM
dbacp04212 LL-III/2 NVWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 7 ± 2 µM
dbacp04213 LL-III/22 KNWKK-Aib-LKK-Aib-IK-Aib-VK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 11 ± 7 µM
dbacp04214 LL-III/22 KNWKK-Aib-LKK-Aib-IK-Aib-VK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp04215 LL-III/22 KNWKK-Aib-LKK-Aib-IK-Aib-VK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 25 ± 4 µM
dbacp04216 LL-III/23 VNWKKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 4 µM
dbacp04217 LL-III/23 VNWKKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 15 µM
dbacp04218 LL-III/23 VNWKKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 6 µM
dbacp04219 LL-III/24 VNWOOILGOIIOVVO Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 ± 1 µM
dbacp04220 LL-III/24 VNWOOILGOIIOVVO Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 20 µM
dbacp04221 LL-III/24 VNWOOILGOIIOVVO Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 5 ± 2 µM
dbacp04222 LL-III/25 vnwkkllgkllkvvk Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 4 ± 2 µM
dbacp04223 LL-III/25 vnwkkllgkllkvvk Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 20 µM
dbacp04224 LL-III/25 vnwkkllgkllkvvk Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 4 µM
dbacp04225 LL-III/26 VYWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 5 ±1 µM
dbacp04226 LL-III/26 VYWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 30 µM
dbacp04227 LL-III/26 VYWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 6 µM
dbacp04228 LL-III/27 VNWKKVLGKVVKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 13 ± 2 µM
dbacp04229 LL-III/27 VNWKKVLGKVVKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp04230 LL-III/27 VNWKKVLGKVVKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 18 µM
dbacp04231 LL-III/3 VNWKKILKKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer Not found
dbacp04232 LL-III/3 VNWKKILKKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp04233 LL-III/3 VNWKKILKKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp04234 LL-III/34 NKWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 5 ± 2 µM
dbacp04235 LL-III/34 NKWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 37 µM
dbacp04236 LL-III/34 NKWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 5 ± 3 µM
dbacp04237 LL-III/36 VNWKKILAKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 µM
dbacp04238 LL-III/36 VNWKKILAKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp04239 LL-III/36 VNWKKILAKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp04240 LL-III/37 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 5 ± 1 µM
dbacp04241 LL-III/37 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 13 µM
dbacp04242 LL-III/37 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 4 ± 1 µM
dbacp04243 LL-III/4 VNWKKILGKIKKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 7 ± 1 µM
dbacp04244 LL-III/4 VNWKKILGKIKKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 40 µM
dbacp04245 LL-III/4 VNWKKILGKIKKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 18 µM
dbacp04246 LL-III/6 VNWKKILPKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 40 µM
dbacp04247 LL-III/6 VNWKKILPKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp04248 LL-III/6 VNWKKILPKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 6 ± 3 µM
dbacp04249 LL-III/8 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 12 ± 1 µM
dbacp04250 LL-III/8 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp04251 LL-III/8 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 9 µM
dbacp04252 LL-III/9 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 ± 1 µM
dbacp04253 LL-III/9 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 25 ± 5 µM
dbacp04254 LL-III/9 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer Not found
dbacp04296 LTX-302 WKKW-Dip-KKWK Synthetic peptide Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 75 ± 5 µM
dbacp04297 LTX-302 WKKW-Dip-KKWK Synthetic peptide Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 73 ± 2 µM
dbacp04298 LTX-302 WKKW-Dip-KKWK Synthetic peptide Cell membrane disintegration MTT/MTS assay Kelly Brain tumor IC50 : 28 ± 0 µM
dbacp04299 LTX-315 KKWWKKW-Dip-K Synthetic peptide Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 38 ± 3 µM
dbacp04300 LTX-315 KKWWKKW-Dip-K Synthetic peptide Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 31 ± 3 µM
dbacp04301 LTX-315 KKWWKKW-Dip-K Synthetic peptide Cell membrane disintegration MTT/MTS assay Kelly Brain tumor IC50 : 14 ± 1 µM
dbacp04302 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay B16F1 Skin cancer IC50 : 13.3 µM
dbacp04303 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay A375 Skin cancer IC50 : 12.7 µM
dbacp04304 LTX-315 KKWWKKW-Dip-K Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : 15.3 µM
dbacp04305 LTX-318 OOW-Dip-OOWWO Synthetic peptide Cell membrane disintegration MTT/MTS assay HT-29 Colon cancer IC50 : 248 ± 5 µM
dbacp04306 LTX-318 OOW-Dip-OOWWO Synthetic peptide Cell membrane disintegration MTT/MTS assay MT-1 Breast cancer IC50 : 216 ± 36 µM
dbacp04307 LTX-318 OOW-Dip-OOWWO Synthetic peptide Cell membrane disintegration MTT/MTS assay Kelly Brain tumor IC50 : 78 ± 7 µM
dbacp04308 LTX-328 KAQ-Dip-QKQAW Synthetic peptide Necrosis MTT/MTS assay Fem-X Skin cancer IC50 : >350 µM
dbacp04376 MAC1 GFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 10 ± 4 µM
dbacp04377 MAC1 GFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 23 ± 4 µM
dbacp04378 MAC1 GFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 12 ± 6 µM
dbacp04379 MAC1/1 gfgmalkllkkvl Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 12 ± 4 µM
dbacp04380 MAC1/1 gfgmalkllkkvl Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 19 ± 2 µM
dbacp04381 MAC1/1 gfgmalkllkkvl Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 11 µM
dbacp04382 MAC1/10 GFKMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ± 6 µM
dbacp04383 MAC1/10 GFKMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer Not found
dbacp04384 MAC1/10 GFKMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 16 µM
dbacp04385 MAC1/16 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 32 ± 2 µM
dbacp04386 MAC1/16 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp04387 MAC1/16 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 70 µM
dbacp04388 MAC1/19 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 21 ± 4 µM
dbacp04389 MAC1/19 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 68 ± 2 µM
dbacp04390 MAC1/19 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 43 ± 11 µM
dbacp04391 MAC1/2 AFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 16 ± 3 µM
dbacp04392 MAC1/2 AFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 16 µM
dbacp04393 MAC1/2 AFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 17 µM
dbacp04394 MAC1/20 GFGMALOLLOOVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 10 ± 1 µM
dbacp04395 MAC1/20 GFGMALOLLOOVL Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 35 ± 4 µM
dbacp04396 MAC1/20 GFGMALOLLOOVL Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 25 ± 3 µM
dbacp04397 MAC1/21 GFGMALRLLRRVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 3 µM
dbacp04398 MAC1/21 GFGMALRLLRRVL Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 17 ± 2 µM
dbacp04399 MAC1/21 GFGMALRLLRRVL Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 22 ± 4 µM
dbacp04400 MAC1/24 GFGMALKL-(AC6C)-KKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 2 µM
dbacp04401 MAC1/24 GFGMALKL-(AC6C)-KKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 16 ± 1 µM
dbacp04402 MAC1/24 GFGMALKL-(AC6C)-KKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 11 µM
dbacp04403 MAC1/25 GFGMALK-(AC6C)-LKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 7 ± 1 µM
dbacp04404 MAC1/25 GFGMALK-(AC6C)-LKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 14 ± 1 µM
dbacp04405 MAC1/25 GFGMALK-(AC6C)-LKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 12 ± 2 µM
dbacp04406 MAC1/26 GFGMA-(AC6C)-KLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 2 µM
dbacp04407 MAC1/26 GFGMA-(AC6C)-KLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 18 ± 1 µM
dbacp04408 MAC1/26 GFGMA-(AC6C)-KLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 9 ± 2 µM
dbacp04409 MAC1/3 LFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 2 µM
dbacp04410 MAC1/3 LFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 11 ± 1 µM
dbacp04411 MAC1/3 LFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 22 µM
dbacp04412 MAC1/4 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ± 5 µM
dbacp04413 MAC1/4 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 49 ± 9 µM
dbacp04414 MAC1/4 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 29 µM
dbacp04415 MAC1/6 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 2 µM
dbacp04416 MAC1/6 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 29 ± 3 µM
dbacp04417 MAC1/6 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 15 µM
dbacp04418 MAC1/9 GFKMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 1 µM
dbacp04419 MAC1/9 GFKMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : 13 ± 3 µM
dbacp04420 MAC1/9 GFKMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 14 ± 4 µM
dbacp04421 MAC2 GTGLPMSERRKIMLMMR Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 100 µM
dbacp04422 MAC2 GTGLPMSERRKIMLMMR Wallabies and their analogs Cell membrane damage MTT/MTS assay SW Colon cancer IC50 : > 100 µM
dbacp04423 MAC2 GTGLPMSERRKIMLMMR Wallabies and their analogs Cell membrane damage MTT/MTS assay CCRF-CEM Leukemia cancer IC50 : 32 µM
dbacp04486 Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS African clawed frog Not specified MTT/MTS assay A-549 Lung cancer IC50 : 110 µM
dbacp04499 Magainin A AIGKFLHSAKKFGKAFVGEIMNS African clawed frog Not specified MTT/MTS assay NCI-H182 Lung cancer IC50 : 7.28 µM
dbacp04500 Magainin A AIGKFLHSAKKFGKAFVGEIMNS African clawed frog Not specified MTT/MTS assay NCI-H526 Lung cancer IC50 : 11.7 µM
dbacp04501 Magainin A AIGKFLHSAKKFGKAFVGEIMNS African clawed frog Not specified MTT/MTS assay NCI-H678 Lung cancer IC50 : 6.23 µM
dbacp04502 Magainin A AIGKFLHSAKKFGKAFVGEIMNS African clawed frog Not specified MTT/MTS assay NCI-H735 Lung cancer IC50 : 10.4 µM
dbacp04503 Magainin A AIGKFLHSAKKFGKAFVGEIMNS African clawed frog Not specified MTT/MTS assay NCI-H841 Lung cancer IC50 : 9.7 µM
dbacp04504 Magainin A AIGKFLHSAKKFGKAFVGEIMNS African clawed frog Not specified MTT/MTS assay NCI-H889 Lung cancer IC50 : 6.56 µM
dbacp04525 Magainin G GIGKFLHSAKKFAKAFVAEIMNS African clawed frog Not specified MTT/MTS assay NCI-H182 Lung cancer IC50 : 12.5 µM
dbacp04526 Magainin G GIGKFLHSAKKFAKAFVAEIMNS African clawed frog Not specified MTT/MTS assay NCI-H526 Lung cancer IC50 : 10.5 µM
dbacp04527 Magainin G GIGKFLHSAKKFAKAFVAEIMNS African clawed frog Not specified MTT/MTS assay NCI-H678 Lung cancer IC50 : 4.44 µM
dbacp04528 Magainin G GIGKFLHSAKKFAKAFVAEIMNS African clawed frog Not specified MTT/MTS assay NCI-H735 Lung cancer IC50 : 7.23 µM
dbacp04529 Magainin G GIGKFLHSAKKFAKAFVAEIMNS African clawed frog Not specified MTT/MTS assay NCI-H841 Lung cancer IC50 : 11.7 µM
dbacp04530 Magainin G GIGKFLHSAKKFAKAFVAEIMNS African clawed frog Not specified MTT/MTS assay NCI-H889 Lung cancer IC50 : 6.57 µM
dbacp04553 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : >80% at 25 µM
dbacp04554 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : ~50% at 50 µM
dbacp04555 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : <40% at 75 µM
dbacp04556 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : >20% at 100 µM
dbacp04557 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : ~100% at 25 µM
dbacp04558 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer IC50 :61.5 µM
dbacp04559 MAP-04-04 KRLRRVWRRWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : > 80% at 50 µM
dbacp04560 MAP-04-04 KRLRRVWRRWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : > 80% at 75 µM
dbacp04561 MAP-04-04 KRLRRVWRRWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : > 80% at 100 µM
dbacp04569 Mastoparan INLKALAALAKKIL-NH2 Eusocial wasp Induction of apoptosis; Alteration of mitochondrial permeability MTS assay A549 Lung cancer IC50 : 34.3 ± 1.6 µg/mL
dbacp04607 Maximin1 GIGTKILGGVKTALKGALKELASTYAN Yunnan firebelly toad Not specified MTT/MTS assay C8166 Leukemia cancer IC50 : 15.3 µg/ml
dbacp04608 Maximin1 GIGTKILGGVKTALKGALKELASTYAN Yunnan firebelly toad Not specified MTT/MTS assay MOLT-4 Leukemia cancer IC50 : 24.3 µg/ml
dbacp04609 Maximin1 GIGTKILGGVKTALKGALKELASTYAN Yunnan firebelly toad Not specified MTT/MTS assay BIU-87 Bladder cancer IC50 : 20.5 µg/ml
dbacp04610 Maximin1 GIGTKILGGVKTALKGALKELASTYAN Yunnan firebelly toad Not specified MTT/MTS assay T-24 Bladder cancer IC50 : 35.4 µg/ml
dbacp04611 Maximin3 GIGGKILSGLKTALKGAAKELASTYLH Yunnan firebelly toad Not specified MTT/MTS assay C8166 Leukemia cancer IC50 : 11.4 µg/ml
dbacp04612 Maximin3 GIGGKILSGLKTALKGAAKELASTYLH Yunnan firebelly toad Not specified MTT/MTS assay MOLT-4 Leukemia cancer IC50 : 25.2 µg/ml
dbacp04613 Maximin3 GIGGKILSGLKTALKGAAKELASTYLH Yunnan firebelly toad Not specified MTT/MTS assay BIU-87 Bladder cancer IC50 : 28 µg/ml
dbacp04614 Maximin3 GIGGKILSGLKTALKGAAKELASTYLH Yunnan firebelly toad Not specified MTT/MTS assay T-24 Bladder cancer IC50 : 18 µg/ml
dbacp04615 Maximin4 GIGVLLSAGKAALKGLAKVLAEKYAN Yunnan firebelly toad Not specified MTT/MTS assay C8166 Leukemia cancer IC50 : 24.2 µg/ml
dbacp04616 Maximin4 GIGVLLSAGKAALKGLAKVLAEKYAN Yunnan firebelly toad Not specified MTT/MTS assay MOLT-4 Leukemia cancer IC50 : 53.4 µg/ml
dbacp04617 Maximin4 GIGVLLSAGKAALKGLAKVLAEKYAN Yunnan firebelly toad Not specified MTT/MTS assay BIU-87 Bladder cancer IC50 : >50 µg/ml
dbacp04618 Maximin4 GIGVLLSAGKAALKGLAKVLAEKYAN Yunnan firebelly toad Not specified MTT/MTS assay T-24 Bladder cancer IC50 : >50 µg/ml
dbacp04619 Maximin5 SIGAKILGGVKTFFKGALKELASTYLQ Yunnan firebelly toad Not specified MTT/MTS assay C8166 Leukemia cancer IC50 : 34.4 µg/ml
dbacp04620 Maximin5 SIGAKILGGVKTFFKGALKELASTYLQ Yunnan firebelly toad Not specified MTT/MTS assay MOLT-4 Leukemia cancer IC50 : >50 µg/ml
dbacp04621 Maximin5 SIGAKILGGVKTFFKGALKELASTYLQ Yunnan firebelly toad Not specified MTT/MTS assay BIU-87 Bladder cancer IC50 : >50 µg/ml
dbacp04622 Maximin5 SIGAKILGGVKTFFKGALKELASTYLQ Yunnan firebelly toad Not specified MTT/MTS assay T-24 Bladder cancer IC50 : >50 µg/ml
dbacp04642 MEL-dKLA GIGAVLKVLTTGLPALISWIKRKRQQGGGGSKLAKLAKKLAKLAK Venom base Inducing apoptosis MTS assay RAW264.7 Lung cancer IC50 : 0.85 μM
dbacp04643 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :3.2 ± 0.1 µM
dbacp04644 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :2.1 ± 0.1 µM
dbacp04645 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :1.8 ± 0.1 µM
dbacp04646 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 :1.4 ± 0.1 µM
dbacp04647 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 1.4 ± 0.1 µM
dbacp04648 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 3.2 ± 0.1 µM
dbacp04649 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 2.1 ± 0.1 µM
dbacp04650 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 1.8 ± 0.1 µM
dbacp04651 Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Natural component of bee venom Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 1.4 ± 0.1 µM
dbacp04677 MG2d GIGKFLHSAKKWGKAFVGQIMNC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 1 µM 90-100% viablity
dbacp04701 mPep1 RKAFRWAWRMLKKAAPSITCVR Bovine lactoferrin (Lf-B) Necrotic cell death by destroying cellular membrane structure; Apoptotic cell death MTT/MTS assay HL-60 Skin cancer IC50 :8 µM
dbacp04711 MSI-136 GIGKFLKKAKKFAKAFVKIINN African clawed frog Not specified MTT/MTS assay A-549 Lung cancer IC50 : 10 µM
dbacp04712 MSI-238 gigkflkkakkfakafvkiinn African clawed frog Not specified MTT/MTS assay A-549 Lung cancer IC50 : 6 µM
dbacp04713 mt_E17L/L22 W/P27A LTFSDWWKLLAE MDM3 Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 15.1 µM
dbacp04714 mt_L22 W/P27A ETFSDWWKLLAE MDM2 Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 16.3 µM
dbacp04715 mt_S20A/L22 W/P27A ETFADWWKLLAE MDM5 Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 8.7 µM
dbacp04716 mt_T18S/L22 W/P27A ESFSDWWKLLAE MDM4 Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 27 µM
dbacp04730 N-1 WKLFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 9.5 µM
dbacp04731 N-1 WKLFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 12 µM
dbacp04732 N-1 WKLFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 6 µM
dbacp04733 N-2 FKLFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 11 µM
dbacp04734 N-2 FKLFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 11 µM
dbacp04735 N-2 FKLFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 7 µM
dbacp04736 N-3 KWFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 17 µM
dbacp04737 N-3 KWFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 17 µM
dbacp04738 N-3 KWFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 11 µM
dbacp04739 N-3L WFKKIPKFLHLLKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 5 µM
dbacp04740 N-3L KWFKKIPKFLHLLKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 4 µM
dbacp04741 N-3L KWFKKIPKFLHLLKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 4.2 µM
dbacp04742 N-4 WFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 32 µM
dbacp04743 N-4 WFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 23 µM
dbacp04744 N-4 WFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 24 µM
dbacp04745 N-4L WKKIPKFLHLLKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 5 µM
dbacp04746 N-4L WFKKIPKFLHLLKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 6 µM
dbacp04747 N-4L WFKKIPKFLHLLKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 3 µM
dbacp04748 N-5 WKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : < 100 µM
dbacp04749 N-5 WKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : < 100 µM
dbacp04750 N-5 WKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : < 100 µM
dbacp04751 N-5L WKKIPKFLHLLKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 :17 µM
dbacp04752 N-5L WKKIPKFLHLLKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 :14 µM
dbacp04753 N-5L WKKIPKFLHLLKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 :10 µM
dbacp04851 NK-11 KISKRILTGKK NK2 derived iNot foundctive control peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : > 100 µM
dbacp04852 NK-11 KISKRILTGKK NK2 derived iNot foundctive control peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : > 100 µM
dbacp04853 NK-11 KISKRILTGKK NK2 derived iNot foundctive control peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : > 100 µM
dbacp04854 NK-11 KISKRILTGKK NK2 derived iNot foundctive control peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : > 100 µM
dbacp04855 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 70 µM
dbacp04856 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM
dbacp04857 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM
dbacp04858 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 40 µM
dbacp04859 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 4.3±0.3 µM
dbacp04860 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 70 µM (approx.)
dbacp04861 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM (approx.)
dbacp04862 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 50 µM (approx.)
dbacp04863 NK-2 KILRGVCKKIMRTFLRRISKDILTGKK Residue of 39-65 of porcine NK-lysine Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : 40 µM (approx.)
dbacp04880 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04881 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04882 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04883 NK11 KISKRILTGKK Synthetic peptide Physical membrane disruption MTT/MTS assay E42/02 Skin cancer IC50 : >100 µM
dbacp04884 Non-digestible fraction peptide GLTSK Common bean Cell proliferation inhibition; Apoptosis inducing MTS assay HCT116 Colorectal cancer IC50 : 0.51 mg/ml
dbacp04885 Non-digestible fraction peptide LSGNK Common bean Cell proliferation inhibition; Apoptosis inducing MTS assay HCT116 Colorectal cancer IC50 : 0.51 mg/ml
dbacp04886 Non-digestible fraction peptide GEGSGA Common bean Cell proliferation inhibition; Apoptosis inducing MTS assay HCT116 Colorectal cancer IC50 : 0.51 mg/ml
dbacp04887 Non-digestible fraction peptide MPACGSS Common bean Cell proliferation inhibition; Apoptosis inducing MTS assay HCT116 Colorectal cancer IC50 : 0.51 mg/ml
dbacp04888 Non-digestible fraction peptide MTEEY Common bean Cell proliferation inhibition; Apoptosis inducing MTS assay HCT116 Colorectal cancer IC50 : 0.51 mg/ml
dbacp04909 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 5 µM
dbacp04910 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 10 µM
dbacp04911 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 30-35% Cytotoxic at 25 µM
dbacp04912 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 60% Cytotoxic at 50 µM
dbacp04913 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 5-10% Cytotoxic at 5 µM
dbacp04914 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 10% Cytotoxic at 10 µM
dbacp04915 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 30-35% Cytotoxic at 25 µM
dbacp04916 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 60% Cytotoxic at 50 µM
dbacp04917 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 30% Cytotoxic at 5 µM
dbacp04918 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 50% Cytotoxic at 10 µM
dbacp04919 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 70% Cytotoxic at 25 µM
dbacp04920 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 80-85% Cytotoxic at 50 µM
dbacp04921 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 30% Cytotoxic at 5 µM
dbacp04922 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 40-50% Cytotoxic at 10 µM
dbacp04923 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 60-70% Cytotoxic at 25 µM
dbacp04924 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 80-85% Cytotoxic at 50 µM
dbacp04925 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 15-20% Cytotoxic at 5 µM
dbacp04926 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 40-50% Cytotoxic at 10 µM
dbacp04927 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 80% Cytotoxic at 25 µM
dbacp04928 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 85-90% Cytotoxic at 50 µM
dbacp04929 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7 Breast cancer 70% Cytotoxic at 50 µM
dbacp04930 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7-TX400 Breast cancer 60-70% Cytotoxic at 50 µM
dbacp04931 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL-NH2 PseudopWinter flounder Cell membrane damage MTT/MTS assay MCF-7-TX400 Breast cancer 60-70% Cytotoxic at 50 µM
dbacp04932 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 5 µM
dbacp04933 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 10 µM
dbacp04934 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 30-35% Cytotoxic at 25 µM
dbacp04935 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 60% Cytotoxic at 50 µM
dbacp04936 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 5-10% Cytotoxic at 5 µM
dbacp04937 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 10% Cytotoxic at 10 µM
dbacp04938 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 30-35% Cytotoxic at 25 µM
dbacp04939 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 60% Cytotoxic at 50 µM
dbacp04940 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 30% Cytotoxic at 5 µM
dbacp04941 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 50% Cytotoxic at 10 µM
dbacp04942 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 70% Cytotoxic at 25 µM
dbacp04943 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 80-85% Cytotoxic at 50 µM
dbacp04944 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 30% Cytotoxic at 5 µM
dbacp04945 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 40-50% Cytotoxic at 10 µM
dbacp04946 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 60-70% Cytotoxic at 25 µM
dbacp04947 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 80-85% Cytotoxic at 50 µM
dbacp04948 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 15-20% Cytotoxic at 5 µM
dbacp04949 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 40-50% Cytotoxic at 10 µM
dbacp04950 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 80% Cytotoxic at 25 µM
dbacp04951 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 85-90% Cytotoxic at 50 µM
dbacp04952 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7 Breast cancer 70% Cytotoxic at 50 µM
dbacp04954 NRC-07 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer ~0% Cytotoxic at 5 µM
dbacp04955 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 5% Cytotoxic at 10 µM
dbacp04956 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 20-30% Cytotoxic at 25 µM
dbacp04957 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 40-50% Cytotoxic at 50 µM
dbacp04958 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer ~0% Cytotoxic at 5 µM
dbacp04959 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 10% Cytotoxic at 10 µM
dbacp04960 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 20% Cytotoxic at 25 µM
dbacp04961 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 40-50% Cytotoxic at 50 µM
dbacp04962 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer ~0% Cytotoxic at 5 µM
dbacp04963 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 20% Cytotoxic at 10 µM
dbacp04964 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 70-80% Cytotoxic at 25 µM
dbacp04965 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 80-85% Cytotoxic at 50 µM
dbacp04966 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 10% Cytotoxic at 5 µM
dbacp04967 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 50% Cytotoxic at 10 µM
dbacp04968 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 80% Cytotoxic at 25 µM
dbacp04969 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 80-90% Cytotoxic at 50 µM
dbacp04970 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 30-40% Cytotoxic at 5 µM
dbacp04971 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 60-70% Cytotoxic at 10 µM
dbacp04972 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 80-90% Cytotoxic at 25 µM
dbacp04973 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 85-90% Cytotoxic at 50 µM
dbacp04974 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7 Breast cancer 70% Cytotoxic at 50 µM
dbacp04975 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7-TX400 Breast cancer 60-70% Cytotoxic at 50 µM
dbacp04976 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 80% Cytotoxic at 25 µM
dbacp04977 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer ~5% Cytotoxic at 10 µM
dbacp04978 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 10% Cytotoxic at 25 µM
dbacp04979 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-231 Breast cancer 10-15% Cytotoxic at 50 µM
dbacp04980 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer ~0% Cytotoxic at 5 µM
dbacp04981 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer ~0% Cytotoxic at 10 µM
dbacp04982 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 10% Cytotoxic at 25 µM
dbacp04983 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay T-47D Breast cancer 10-15% Cytotoxic at 50 µM
dbacp04984 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 10% Cytotoxic at 5 µM
dbacp04985 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 10% Cytotoxic at 10 µM
dbacp04986 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 10-15% Cytotoxic at 25 µM
dbacp04987 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay SKBR-3 Breast cancer 15-20% Cytotoxic at 50 µM
dbacp04988 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer ~5% Cytotoxic at 5 µM
dbacp04989 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer ~5% Cytotoxic at 10 µM
dbacp04990 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 5% Cytotoxic at 25 µM
dbacp04991 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MDA-MB-468 Breast cancer 10-15% Cytotoxic at 50 µM
dbacp04992 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer ~0% Cytotoxic at 5 µM
dbacp04993 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer ~0% Cytotoxic at 10 µM
dbacp04994 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 5-10% Cytotoxic at 25 µM
dbacp04995 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay 4T1 Breast cancer 20% Cytotoxic at 50 µM
dbacp04996 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7 Breast cancer 0% Cytotoxic at 50 µM
dbacp04997 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7-TX400 Breast cancer ~5% Cytotoxic at 50 µM
dbacp05012 Omiganan MBI-226 ILRWPWWPWRRK Cattle neutrophils Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer IC50 : 80 - 85 µg/ml
dbacp05013 Omiganan MBI-226 ILRWPWWPWRRK Helical peptide with a predominance of one or more amino acids tryptophane-rich Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-937 Lymphoma cancer 27% Cytotoxicity at 0.5 µg/ml
dbacp05021 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-549 Lung cancer IC50 : 33 µMo/L
dbacp05022 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay A-375 Skin cancer IC50 : 17.8 µMo/L
dbacp05023 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 15.8 µMo/L
dbacp05024 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay SW-1116 Colorectal cancer IC50 : 11.1 µMo/L
dbacp05025 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay RD Rhabdomyosarcoma cancer IC50 : 25.2 µMo/L
dbacp05026 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay H-1299 Lung cancer IC50 : 4.7 µMo/L
dbacp05027 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay B-16 Skin cancer IC50 : 11.5 µMo/L
dbacp05028 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 10.4 µMo/L
dbacp05032 P1 KWKLFKKIGIGAVLKVLKKG Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H69 Lung cancer IC50 :3.4 µM
dbacp05033 P1 KWKLFKKIGIGAVLKVLKKG Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H128 Lung cancer IC50 :3.5 µM
dbacp05034 P1 KWKLFKKIGIGAVLKVLKKG Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H146 Lung cancer IC50 :4.5 µM
dbacp05038 P18 KWKLFKKIPKFLHLAKKF Bovine lactoferrin (Lf-B) Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 92.2 ± 1.02% cell viability at 10 µM
dbacp05039 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 71.1 ± 2.84% cell viability at 20 µM
dbacp05040 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 50 ± 3.09% cell viability at 40 µM
dbacp05041 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 31.5 ± 1.49% cell viability at 60 µM
dbacp05042 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay M14 Skin cancer 13.8 ± 1.44% cell viability at 80 µM
dbacp05043 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 86 ± 0.57% cell viability at 10 µM
dbacp05044 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 63.8 ± 0.8% cell viability at 20 µM
dbacp05045 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 47.5 ± 1.66% cell viability at 40 µM
dbacp05046 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 26.9 ± 0.5% cell viability at 60 µM
dbacp05047 P18 KWKLFKKIPKFLHLAKKF Synthetic peptide Necrosis; Cell membrane rupture MTT/MTS assay A-375 Skin cancer 6.5 ± 1.07% cell viability at 80 µM
dbacp05048 P18 KWKFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 8 µM
dbacp05049 P18 KWKFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay Jurkat Blood cancer IC50 : 4 µM
dbacp05050 P18 KWKFKKIPKFLHLAKKF Ceropin A Cell membrane disintegration MTT/MTS assay K-562 Leukemia cancer IC50 : 3.5 µM
dbacp05052 P2 KWKLFKKIGIGKFLHSATTF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H69 Lung cancer IC50 : 36.2 µM
dbacp05053 P2 KWKLFKKIGIGKFLHSATTF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H128 Lung cancer IC50 : 37.9 µM
dbacp05054 P2 KWKLFKKIGIGKFLHSATTF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H146 Lung cancer IC50 : 47.7 µM
dbacp05055 P2 RALGWSCL Plant sources Inducing apoptosis MTS assay NB4 Not specified IC50 : 600 μg/mL
dbacp05056 P2 RALGWSCL Plant sources Inducing apoptosis MTS assay MOLT4 Not specified IC50 : 700 μg/mL
dbacp05057 P2 RALGWSCL Plant sources Inducing apoptosis MTS assay Raji Not specified IC50 : 700 μg/Ml
dbacp05058 P3 KWKLFKKIGIGAFLHSAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H69 Lung cancer IC50 : 9.3 µM
dbacp05059 P3 KWKLFKKIGIGAFLHSAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H128 Lung cancer IC50 : 9.3 µM
dbacp05060 P3 KWKLFKKIGIGAFLHSAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H146 Lung cancer IC50 : 10.9 µM
dbacp05072 P4 KWKLFKKIGIGKFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H69 Lung cancer IC50 : 1.9 µM
dbacp05073 P4 KWKLFKKIGIGKFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H128 Lung cancer IC50 : 1.3 µM
dbacp05074 P4 KWKLFKKIGIGKFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H146 Lung cancer IC50 : 2.8 µM
dbacp05075 P5 KWKLFKKIGIGAFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H69 Lung cancer IC50 : 2.9 µM
dbacp05076 P5 KWKLFKKIGIGAFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H128 Lung cancer IC50 : 2.9 µM
dbacp05077 P5 KWKLFKKIGIGAFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H146 Lung cancer IC50 : 3.2 µM
dbacp05086 P6 KWKLFKKIGIGKFKLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H69 Lung cancer IC50 : 1.7 µM
dbacp05087 P6 KWKLFKKIGIGKFKLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H128 Lung cancer IC50 : 2 µM
dbacp05088 P6 KWKLFKKIGIGKFKLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H146 Lung cancer IC50 : 3.1 µM
dbacp05095 P7 KWKLFAKIGIGKFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H69 Lung cancer IC50 : 3.1 µM
dbacp05096 P7 KWKLFAKIGIGKFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H128 Lung cancer IC50 : 2.4 µM
dbacp05097 P7 KWKLFAKIGIGKFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H146 Lung cancer IC50 : 2.4 µM
dbacp05099 P8 KWKKFLKIGIGKFLHLAKKF Ceropin A-African clawed frog Apoptosis MTT/MTS assay NCI-H69 Lung cancer IC50 : 2.6 µM
dbacp05100 P8 KWKKFLKIGIGKFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H128 Lung cancer IC50 : 2.3 µM
dbacp05101 P8 KWKKFLKIGIGKFLHLAKKF Ceropin A-African clawed frog Apoptosis inducing MTT/MTS assay NCI-H146 Lung cancer IC50 : 1.8 µM
dbacp05134 Pardaxin GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Red sea moses sole Inducing apoptosis MTT/MTS assay HT-1080 Fibrosarcoma IC50 : 15.74 µg/ml
dbacp05135 Pardaxin GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Red sea moses sole Inducing apoptosis MTT/MTS assay HT-1080 Fibrosarcoma IC50 : 15.40 µg/ml
dbacp05136 Pardaxin GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Red sea moses sole Inducing apoptosis MTT/MTS assay HT-1080 Fibrosarcoma IC50 : 14.51 µg/ml
dbacp05137 Pardaxin GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Red sea moses sole Inducing apoptosis MTT/MTS assay HT-1080 Fibrosarcoma IC50 : 14.52 µg/ml
dbacp05139 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 62 % Cytotoxicity at 50 mg/L
dbacp05140 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 44 % Cytotoxicity at 25 mg/L
dbacp05141 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 12.5 mg/L
dbacp05142 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75 % Cytotoxicity at 50 mg/L
dbacp05143 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp05144 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 3.125 mg/L
dbacp05145 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 78 % Cytotoxicity at 50 mg/L
dbacp05146 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 68 % Cytotoxicity at 25 mg/L
dbacp05147 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 12.5 mg/L
dbacp05148 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 6.25 mg/L
dbacp05149 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 3.125 mg/L
dbacp05150 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 90 % Cytotoxicity at 50 mg/L
dbacp05151 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 80 % Cytotoxicity at 25 mg/L
dbacp05152 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 15 % Cytotoxicity at 12.5 mg/L
dbacp05153 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 12 % Cytotoxicity at 6.25 mg/L
dbacp05154 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 3.125 mg/L
dbacp05155 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 88 % Cytotoxicity at 50 mg/L
dbacp05156 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 82 % Cytotoxicity at 25 mg/L
dbacp05157 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 40 % Cytotoxicity at 12.5 mg/L
dbacp05158 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 35 % Cytotoxicity at 6.25 mg/L
dbacp05159 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 35 % Cytotoxicity at 3.125 mg/L
dbacp05160 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 90 % Cytotoxicity at 50 mg/L
dbacp05161 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 90 % Cytotoxicity at 25 mg/L
dbacp05162 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 30 % Cytotoxicity at 12.5 mg/L
dbacp05163 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 30 % Cytotoxicity at 6.25 mg/L
dbacp05164 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 30 % Cytotoxicity at 3.125 mg/L
dbacp05165 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 97 % Cytotoxicity at 50 mg/L
dbacp05166 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 95 % Cytotoxicity at 25 mg/L
dbacp05167 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 39 % Cytotoxicity at 12.5 mg/L
dbacp05168 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 28 % Cytotoxicity at 6.25 mg/L
dbacp05169 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 38 % Cytotoxicity at 3.125 mg/L
dbacp05170 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 90 % Cytotoxicity at 50 mg/L
dbacp05171 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 90 % Cytotoxicity at 25 mg/L
dbacp05172 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 15 % Cytotoxicity at 12.5 mg/L
dbacp05173 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 5 % Cytotoxicity at 6.25 mg/L
dbacp05174 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 10 % Cytotoxicity at 3.125 mg/L
dbacp05175 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 50 mg/L
dbacp05176 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 60 % Cytotoxicity at 25 mg/L
dbacp05177 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 12.5 mg/L
dbacp05178 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 6.25 mg/L
dbacp05179 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 1 % Cytotoxicity at 3.125 mg/L
dbacp05180 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 78 % Cytotoxicity at 50 mg/L
dbacp05181 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp05182 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 12.5 mg/L
dbacp05183 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 6.25 mg/L
dbacp05184 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 3.125 mg/L
dbacp05185 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 82 % Cytotoxicity at 50 mg/L
dbacp05186 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp05187 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 18 % Cytotoxicity at 12.5 mg/L
dbacp05188 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 6.25 mg/L
dbacp05189 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 3.125 mg/L
dbacp05190 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 90 % Cytotoxicity at 50 mg/L
dbacp05191 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 82 % Cytotoxicity at 25 mg/L
dbacp05192 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 18 % Cytotoxicity at 12.5 mg/L
dbacp05193 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 18 % Cytotoxicity at 6.25 mg/L
dbacp05194 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 18 % Cytotoxicity at 3.125 mg/L
dbacp05195 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 80 % Cytotoxicity at 50 mg/L
dbacp05196 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 85 % Cytotoxicity at 25 mg/L
dbacp05197 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 45 % Cytotoxicity at 12.5 mg/L
dbacp05198 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 30 % Cytotoxicity at 6.25 mg/L
dbacp05199 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 25 % Cytotoxicity at 3.125 mg/L
dbacp05200 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 84 % Cytotoxicity at 50 mg/L
dbacp05201 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 84% Cytotoxicity at 25 mg/L
dbacp05202 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 48 % Cytotoxicity at 12.5 mg/L
dbacp05203 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 30 % Cytotoxicity at 6.25 mg/L
dbacp05204 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 35 % Cytotoxicity at 3.125 mg/L
dbacp05205 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 90 % Cytotoxicity at 50 mg/L
dbacp05206 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 85 % Cytotoxicity at 25 mg/L
dbacp05207 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 30 % Cytotoxicity at 12.5 mg/L
dbacp05208 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 35 % Cytotoxicity at 6.25 mg/L
dbacp05209 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 15 % Cytotoxicity at 3.125 mg/L
dbacp05210 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 90 % Cytotoxicity at 50 mg/L
dbacp05211 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 90 % Cytotoxicity at 25 mg/L
dbacp05212 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 20 % Cytotoxicity at 12.5 mg/L
dbacp05213 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 1 % Cytotoxicity at 6.25 mg/L
dbacp05214 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HT-1080 Fibrosarcoma 10 % Cytotoxicity at 3.125 mg/L
dbacp05245 pep1 FKCRRWQWRMKKLGAPSITCVR Bovine lactoferrin (Lf-B) Activating an apoptosis-inducing pathway MTT/MTS assay HL-60 Prostate cancer IC50 :77 µM
dbacp05246 Pep27 MRKEFHNVLSSGQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay AML-2 Leukemia cancer Not found
dbacp05247 Pep27 MRKEFHNVLSSGQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay HL-60 Leukemia cancer IC50 : > 70 µM
dbacp05248 Pep27 MRKEFHNVLSSGQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay Jurkat Blood cancer IC50 : > 70 µM
dbacp05249 Pep27 MRKEFHNVLSSGQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay SNU-601 Gastric cancer IC50 : > 70 µM
dbacp05250 Pep27 MRKEFHNVLSSGQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : > 70 µM
dbacp05256 Pep27 MRKEFHNVLSSGQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : > 70 µM
dbacp05282 Pep27anal1 MWKWFHNVLSSWQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay AML-2 Leukemia cancer IC50 : 50 µM
dbacp05283 Pep27anal1 MWKWFHNVLSSWQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay HL-60 Leukemia cancer IC50 : 53 µM
dbacp05284 Pep27anal1 MWKWFHNVLSSWQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay Jurkat Blood cancer IC50 : 47 µM
dbacp05285 Pep27anal1 MWKWFHNVLSSWQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay SNU-601 Gastric cancer IC50 : 37 µM
dbacp05286 Pep27anal1 MWKWFHNVLSSWQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 55 µM
dbacp05287 Pep27anal2 MWKWFHNVLSWWWLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay AML-2 Leukemia cancer IC50 : 29 µM
dbacp05288 Pep27anal2 MWKWFHNVLSWWWLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay HL-60 Leukemia cancer IC50 : 20 µM
dbacp05289 Pep27anal2 MWKWFHNVLSWWWLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay Jurkat Blood cancer IC50 : 23 µM
dbacp05290 Pep27anal2 MWKWFHNVLSWWWLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay SNU-601 Gastric cancer IC50 : 25 µM
dbacp05291 Pep27anal2 MWKWFHNVLSWWWLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : < 10 µM
dbacp05292 Pep27anal3 MRKWFHNVLSSGQLLADKWPAWDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay AML-2 Leukemia cancer IC50 : 67 µM
dbacp05293 Pep27anal3 MRKWFHNVLSSGQLLADKWPAWDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay HL-60 Leukemia cancer IC50 : 52 µM
dbacp05294 Pep27anal3 MRKWFHNVLSSGQLLADKWPAWDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay Jurkat Blood cancer IC50 : 50 µM
dbacp05295 Pep27anal3 MRKWFHNVLSSGQLLADKWPAWDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay SNU-601 Gastric cancer IC50 : 50 µM
dbacp05296 Pep27anal3 MRKWFHNVLSSGQLLADKWPAWDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 38 µM
dbacp05297 Pep27anal4 MWKEFHNVLSSGQLLADKRWARWYNRW Pneumococcus Apoptosis inducing MTT/MTS assay AML-2 Leukemia cancer IC50 : 50 µM
dbacp05298 Pep27anal4 MWKEFHNVLSSGQLLADKRWARWYNRW Pneumococcus Apoptosis inducing MTT/MTS assay HL-60 Leukemia cancer IC50 : 51 µM
dbacp05299 Pep27anal4 MWKEFHNVLSSGQLLADKRWARWYNRW Pneumococcus Apoptosis inducing MTT/MTS assay Jurkat Blood cancer IC50 : 46 µM
dbacp05300 Pep27anal4 MWKEFHNVLSSGQLLADKRWARWYNRW Pneumococcus Apoptosis inducing MTT/MTS assay SNU-601 Gastric cancer IC50 : 37 µM
dbacp05301 Pep27anal4 MWKEFHNVLSSGQLLADKRWARWYNRW Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 29 µM
dbacp05302 Pep27anal5 MWKWFHNVLSSGQLLADKWWAWWYNWW Pneumococcus Apoptosis inducing MTT/MTS assay AML-2 Leukemia cancer IC50 : >70 µM
dbacp05303 Pep27anal5 MWKWFHNVLSSGQLLADKWWAWWYNWW Pneumococcus Apoptosis inducing MTT/MTS assay HL-60 Leukemia cancer IC50 : >70 µM
dbacp05304 Pep27anal5 MWKWFHNVLSSGQLLADKWWAWWYNWW Pneumococcus Apoptosis inducing MTT/MTS assay Jurkat Blood cancer IC50 : >70 µM
dbacp05305 Pep27anal5 MWKWFHNVLSSGQLLADKWWAWWYNWW Pneumococcus Apoptosis inducing MTT/MTS assay SNU-601 Gastric cancer IC50 : >70 µM
dbacp05306 Pep27anal5 MWKWFHNVLSSGQLLADKWWAWWYNWW Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : >70 µM
dbacp05307 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 10.6 % inhibition of cell proliferation at 1 nM
dbacp05308 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 18.2 % inhibition of cell proliferation at 10 nM
dbacp05309 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 30.7 % inhibition of cell proliferation at 100 nM
dbacp05310 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 43.1 % inhibition of cell proliferation at 1 µM
dbacp05311 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer 98.3 % inhibition of cell proliferation at 10 µM
dbacp05312 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 24.2 % inhibition of cell proliferation at 1 nM
dbacp05313 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 37.8 % inhibition of cell proliferation at 10 nM
dbacp05314 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 48.2 % inhibition of cell proliferation at 100 nM
dbacp05315 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 59.6 % inhibition of cell proliferation at 1 µM
dbacp05316 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer 84.5 % inhibition of cell proliferation at 10 µM
dbacp05317 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 16.5 % inhibition of cell proliferation at 1 nM
dbacp05318 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 14.2 % inhibition of cell proliferation at 10 nM
dbacp05319 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 16.8 % inhibition of cell proliferation at 100 nM
dbacp05320 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 21.7 % inhibition of cell proliferation at 1 µM
dbacp05321 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer 27.9 % inhibition of cell proliferation at 10 µM
dbacp05322 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 10.4 % inhibition of cell proliferation at 1 nM
dbacp05323 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 18.7 % inhibition of cell proliferation at 10 nM
dbacp05324 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 34.7 % inhibition of cell proliferation at 100 nM
dbacp05325 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 54.3 % inhibition of cell proliferation at 1 µM
dbacp05326 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer 94.5 % inhibition of cell proliferation at 10 µM
dbacp05327 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay KB Oral cancer ED50 : 2.1 µM
dbacp05328 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MiaPaCa.2 Pancreatic cancer ED50 : 0.210 µM
dbacp05329 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay PTC Colon cancer ED50 : >10 µM
dbacp05330 Peptide 5 fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin Not specified MTT/MTS assay MOLT-4 Leukemia cancer ED50 : 0.29 µM
dbacp05405 Peptide K14D KWKSFLKTFKSLKkTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.52 ± 0.05 µMol/L
dbacp05406 Peptide K14D/K22D KWKSFLKTFKSLKkTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.40 ± 0.09 µMol/L
dbacp05407 Peptide K1D/K3D/K7D /K10D/K14D/K22D kWkSFLkTFkSLKkTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 18.07 ± 0.48 µMol/L
dbacp05408 Peptide K22D KWKSFLKTFKSLKKTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.39 ± 0.02 µMol/L
dbacp05409 Peptide K3D/K7D /K10D/K14D/K22D KWkSFLkTFkSLKkTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 20.41 ± 0.64 µMol/L
dbacp05410 Peptide K7D KWKSFLkTFKSLKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.29 ± 0.03 µMol/L
dbacp05411 Peptide K7D /K10D/K14D/K22D KWKSFLkTFkSLKkTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 4.79 ± 0.23 µMol/L
dbacp05412 Peptide K7D /K14D KWKSFLkTFKSLKkTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.06 ± 0.01 µMol/L
dbacp05413 Peptide K7D /K14D/K22D KWKSFLkTFKSLKkTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 4.45 ± 0.19 µMol/L
dbacp05414 Peptide L12D KWKSFLKTFKSlKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.63 ± 0.07 µMol/L
dbacp05415 Peptide L12D/L20D KWKSFLKTFKSlKKTVLHTlLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 3.14 ± 0.06 µMol/L
dbacp05416 Peptide L20D KWKSFLKTFKSLKKTVLHTlLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.33 ± 0.06 µMol/L
dbacp05417 Peptide L6D KWKSFlKTFKSLKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.23 ± 0.10 µMol/L
dbacp05418 Peptide L6D/L12D KWKSFlKTFKSlKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 3.01 ± 0.08 µMol/L
dbacp05419 Peptide L6D/L12D/L17D/L20D KWKSFlKTFKSlKKTVlHTlLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 9.69 ± 0.38 µMol/L
dbacp05420 Peptide L6D/L12D/L17D/L20D/L21D KWKSFlKTFKSlKKTVlHTllKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 12.88 ± 0.15 µMol/L
dbacp05421 Peptide L6D/L12D/L20D KWKSFlKTFKSlKKTVLHTlLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 7.80 ± 0.26 µMol/L
dbacp05427 Peptide P KWKSFLKTFKSLKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.71 ± 0.07 µMol/L
dbacp05434 Peptide-1 IELLQARGGC-Pem Synthetic construct Cell membrane disintegration MTT/MTS assay HL-60 Leukemia cancer IC50 : 2.17 µM
dbacp05435 Peptide-1 IELLQARGGC-Pem Synthetic construct Cell membrane disintegration MTT/MTS assay NCI-H358 Lung cancer IC50 : 4.63 mM
dbacp05436 Peptide-2 IELLQARGGC-Pem-GGRRRRRRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HL-60 Leukemia cancer IC50 : 2.64 µM
dbacp05437 Peptide-2 IELLQARGGC-Pem-GGRRRRRRRR Synthetic construct Cell membrane disintegration MTT/MTS assay NCI-H358 Lung cancer IC50 : 2.19 µM
dbacp05438 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay HL-60 Leukemia cancer At 100 µM 90% viablity
dbacp05439 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay MDA-MB-231 Breast cancer At 100 µM 55% viablity
dbacp05440 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay HeLa Cervical cancer At 100 µM 50% viablity
dbacp05441 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay B16F10-Nex 2 Skin cancer At 100 µM 50% viablity
dbacp05442 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay A-2058 Skin cancer At100 µM 30% viablity
dbacp05443 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay Skmel-25 Skin cancer At 100 µM 55 - 60% viablity
dbacp05444 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay Skmel-28 Skin cancer At 100 µM 35 - 40% viablity
dbacp05445 Peptide-3 RRRRRRRRGGC-Pem Synthetic construct Cell membrane disintegration MTT/MTS assay HL-60 Leukemia cancer IC50 : 6.24 µM
dbacp05446 Peptide-3 RRRRRRRRGGC-Pem Synthetic construct Cell membrane disintegration MTT/MTS assay NCI-H358 Lung cancer IC50 : 8.41 µM
dbacp05484 Pexiganan GIGKFLKKAKKFGKAFVKILKK Analog of African clawed frog Plasma membrane perturbations MTT/MTS assay MCF-7 Breast cancer LC50 : 8 at 100 µM
dbacp05485 Pexiganan GIGKFLKKAKKFGKAFVKILKK Analog of African clawed frog Plasma membrane perturbations MTT/MTS assay LNCaP Prostate cancer LC50 : 6 at 100 µM
dbacp05486 Pexiganan GIGKFLKKAKKFGKAFVKILKK Analog of African clawed frog Plasma membrane perturbations MTT/MTS assay OVRCAR-3 Ovarian cancer LC50 : 13 at 100 µM
dbacp05487 Pexiganan acetate GIGKFLKKAKKFGKAFVKILKK Engineered Disruption of membrane permeability MTT/MTS assay U-937 Lymphoma cancer 75% Cytotoxicity at 0.5 µg/ml
dbacp05488 Pexiganan MSI-78 GIGKFLKKAKKFGKAFVKILKK Analog of African clawed frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-941 Lymphoma cancer IC50 : 20-30 µg/ml
dbacp05489 Pexiganan MSI-78 GIGKFLKKAKKFGKAFVKILKK Helical peptide with a predominance of one or more amino acids tryptophane-rich Disruption of membrane permeability MTT/MTS assay U-937 Lymphoma cancer 75% Cytotoxicity at 0.5 µg/ml
dbacp05565 piscidin-1 FFHHIFRGIVHVGKTIHRLVTG Striped bass fish Apoptosis inducing; Elevation of ROS MTT/MTS assay SCC4 Oral squamous cell carcinoma IC50 : 10.82 – 13.77 μM
dbacp05566 piscidin-1 FFHHIFRGIVHVGKTIHRLVTG Striped bass fish Inhibits angiogenesis; Apoptosis inducing; Elevation of ROS MTT/MTS assay OC2 Oral cancer IC50 : 16.94 – 19.20 μM
dbacp05567 Piscidin-1 FFHHIFRGIVHVGKTIHRLVTG Striped bass x White bass Induce apoptosis; Necrotic activity MTS assay and soft-agar colony-formation assay HT1080 Not specified MIC : 20 μg/ml
dbacp05568 Piscidin-1 FFHHIFRGIVHVGKTIHRLVTG Striped bass x White bass Induce apoptosis; Necrotic activity MTS assay and soft-agar colony-formation assay HeLa Not specified MIC : 25 μg/ml
dbacp05587 PNC-28 ETFSDLWKLL Ant Membrane disruption MTT/MTS assay MiaPaCa.2 Pancreatic cancer Cytotoxicity : 80µg/ml
dbacp05649 Protegrin 1 RGGRLCYCRRRFCVCVGR Alpha helical peptide without cysteines Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-942 Lymphoma cancer IC50 : 30-40 µg/ml
dbacp05650 Protegrin 1 RGGRLCYCRRRFCVCVGR Alpha helical peptide without cysteines Not specified MTT/MTS assay U-937 Lymphoma cancer 61% Cytotoxicity at 0.5 µg/ml
dbacp05694 PST13-RK KKKFPWWWPFKKK Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : 90 µg/ml
dbacp05695 PST13-RK KKKFPWWWPFKKK Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 80 µg/ml
dbacp05706 PTP-7a FLGALFHALSKLL Synthetic peptide Inducing cell membrane damage MTT/MTS assay A-549 Lung cancer IC50 : 28 µM
dbacp05707 PTP-7b FLGALFKALSHLL Synthetic peptide Inducing cell membrane damage MTT/MTS assay A-549 Lung cancer IC50 : 32 µM
dbacp05708 PTP1 LLAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : >100 µg/ml
dbacp05709 PTP1 LLAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay HEK294 Renal cancer IC50 : >100 µg/ml
dbacp05710 PTP1 LLAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay HEK302 Renal cancer IC50 : >100 µg/ml
dbacp05711 PTP1 LLAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : >100 µg/ml
dbacp05712 PTP1 LLAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : >100 µg/ml
dbacp05713 PTP2 FAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : >100 µg/ml
dbacp05714 PTP2 FAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay HEK295 Renal cancer IC50 : >100 µg/ml
dbacp05715 PTP2 FAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay HEK303 Renal cancer IC50 : >100 µg/ml
dbacp05716 PTP2 FAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : >100 µg/ml
dbacp05717 PTP2 FAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : >100 µg/ml
dbacp05718 PTP4 FLKLLKKLAAKFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 13.71 µg/ml
dbacp05719 PTP4 FLKLLKKLAAKFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay HEK296 Renal cancer IC50 : 26.15 µg/ml
dbacp05720 PTP4 FLKLLKKLAAKFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay PC-3 Prostate cancer IC50 : 18.63 µg/ml
dbacp05721 PTP4 FLKLLKKLAAKFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 18.18 µg/ml
dbacp05722 PTP4 FLKLLKKLAAKFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 18.1 µg/ml
dbacp05723 PTP5 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 9.09 µg/ml
dbacp05724 PTP5 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay HEK297 Renal cancer IC50 : 15.11 µg/ml
dbacp05725 PTP5 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay PC-3 Prostate cancer Not found
dbacp05726 PTP5 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer Not found
dbacp05727 PTP5 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 5.43 µg/ml
dbacp05728 PTP6 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 13.94 µg/ml
dbacp05729 PTP6 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay HEK298 Renal cancer IC50 : 14 µg/ml
dbacp05730 PTP6 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay PC-3 Prostate cancer IC50 : 13.27 µg/ml
dbacp05731 PTP6 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 15.07 µg/ml
dbacp05732 PTP6 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 17.56 µg/ml
dbacp05733 PTP7 FLGALFKALSKLL Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 8.01 µg/ml
dbacp05734 PTP7 FLGALFKALSKLL Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay HEK299 Renal cancer IC50 : 6.71 µg/ml
dbacp05735 PTP7 FLGALFKALSKLL Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay PC-3 Prostate cancer IC50 : 5.01 µg/ml
dbacp05736 PTP7 FLGALFKALSKLL Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 5.4 µg/ml
dbacp05737 PTP7 FLGALFKALSKLL Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 5.25 µg/ml
dbacp05738 PTP8 FLKLLAGLLKNFA Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay A-549 Lung cancer IC50 : 24.58 µg/ml
dbacp05739 PTP8 FLKLLAGLLKNFA Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay HEK300 Renal cancer IC50 : 26.8 µg/ml
dbacp05740 PTP8 FLKLLAGLLKNFA Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay PC-3 Prostate cancer IC50 : 28.9 µg/ml
dbacp05741 PTP8 FLKLLAGLLKNFA Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 30.79 µg/ml
dbacp05742 PTP8 FLKLLAGLLKNFA Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 32.23 µg/ml
dbacp05825 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 0% apoptosis at 10 µM
dbacp05826 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 10% apoptosis at 20 µM
dbacp05827 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 30% apoptosis at 50 µM
dbacp05828 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 30% apoptosis at 10 µM
dbacp05829 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 80% apoptosis at 20 µM
dbacp05830 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 80% apoptosis at 50 µM
dbacp05831 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 20% apoptosis at 10 µM
dbacp05832 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor > 50% apoptosis at 20 µM
dbacp05833 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 30% apoptosis at 50 µM
dbacp05834 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 15% apoptosis at 10 µM
dbacp05835 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 20% apoptosis at 20 µM
dbacp05836 R8-BadBH3 rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 50% apoptosis at 50 µM
dbacp05839 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 8% apoptosis at 10 µM
dbacp05840 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 45% apoptosis at 20 µM
dbacp05841 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 65% apoptosis at 50 µM
dbacp05842 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 25% apoptosis at 10 µM
dbacp05843 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 66% apoptosis at 20 µM
dbacp05844 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 68% apoptosis at 50 µM
dbacp05845 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 43% apoptosis at 10 µM
dbacp05846 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 46% apoptosis at 20 µM
dbacp05847 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 79% apoptosis at 50 µM
dbacp05848 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 23% apoptosis at 10 µM
dbacp05849 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 35% apoptosis at 20 µM
dbacp05850 R8-BidBH3 rrrrrrrrGEDIIRNIARHLAQVGDSMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 55% apoptosis at 50 µM
dbacp05851 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 1% apoptosis at 10 µM
dbacp05852 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 2% apoptosis at 20 µM
dbacp05853 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay SK-N-AS Brain tumor 3% apoptosis at 50 µM
dbacp05854 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 2% apoptosis at 10 µM
dbacp05855 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 1% apoptosis at 20 µM
dbacp05856 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NB69 Brain tumor 5% apoptosis at 50 µM
dbacp05857 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 1% apoptosis at 10 µM
dbacp05858 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 2% apoptosis at 20 µM
dbacp05859 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay NGP Tumor 3% apoptosis at 50 µM
dbacp05860 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 0% apoptosis at 10 µM
dbacp05861 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 1% apoptosis at 20 µM
dbacp05862 R8-BidBH3Alt rrrrrrrrGEDIIRNIARHAAQVGASMDR Synthetic Peptide Inducing mitochondrial apoptosis MTT/MTS assay IMR5 Tumor 2% apoptosis at 50 µM
dbacp05928 Red Sea microbiome peptide AAEKEFIKYPYPTPLQYQQLATRLKVEKKLVRRW Red Sea microbiome derived peptide Apoptosis inducing MTT/MTS assay U2OS Osteosarcoma Not found
dbacp05943 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay SW-1116 Colorectal cancer 72.69 Inhibition ratio at 50 µg/ml
dbacp05944 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay SMMC-7721 Liver cancer 70.39 Inhibition ratio at 50 µg/ml
dbacp05945 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer 73.09 Inhibition ratio at 50 µg/ml
dbacp05946 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HepG-2 Liver cancer 60.22 Inhibition ratio at 50 µg/ml
dbacp05947 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay BGC-823 Gastric cancer 62.49 Inhibition ratio at 50 µg/ml
dbacp05948 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay A-549 Lung cancer 47.26Inhibition ratio at 50 µg/ml
dbacp05949 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HL7702 Liver cancer 36.25 Inhibition ratio at 50 µg/ml
dbacp05950 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HEK-293T Renal cancer 27.86 Inhibition ratio at 50 µg/ml
dbacp05951 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay MEC Breast cancer 19.76 Inhibition ratio at 50 µg/ml
dbacp05952 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay SW-1116 Colorectal cancer 81.465 Inhibition ratio at 50 µg/ml
dbacp05953 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay SMMC-7721 Liver cancer 86.175 Inhibition ratio at 50 µg/ml
dbacp05954 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer 78.045 Inhibition ratio at 50 µg/ml
dbacp05955 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HepG-2 Liver cancer 73.07 Inhibition ratio at 50 µg/ml
dbacp05956 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay BGC-823 Gastric cancer 73.705 Inhibition ratio at 50 µg/ml
dbacp05957 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay A-549 Lung cancer 52.50 Inhibition ratio at 50 µg/ml
dbacp05958 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HL7702 Liver cancer 38.13 Inhibition ratio at 50 µg/ml
dbacp05959 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HEK-293T Renal cancer 32.52 Inhibition ratio at 50 µg/ml
dbacp05960 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay MEC Breast cancer 29.33 Inhibition ratio at 50 µg/ml
dbacp05961 RGD-mda-7 MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer Cell viability(% of control):0.5 at concentration 4 µg/ml
dbacp05962 RGD-mda-7 MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). Apoptosis inducing MTT/MTS assay Ket-3 Tumor Cell viability(% of control): 0.5 at concentration 8 µg/ml
dbacp06033 Scolopendrasin VII FCTCNVKGFNAKNKRGIIYP Chinese red-headed centipede, Asia Necrotic cell death MTS assay U937 Leukemia Not found
dbacp06034 Scolopendrasin VII FCTCNVKGFNAKNKRGIIYP Chinese red-headed centipede, Asia Necrotic cell death MTS assay Jurkat Leukemia Not found
dbacp06079 Short α-helical peptide GIIKKIIKKI Alpha-helical proteins Cell membrane disruption; Cell apoptosis MTT/MTS assay HeLa Cervical cancer 99% Cytotoxicity at 4µM approx.
dbacp06080 Short α-helical peptide GIIKKIIKKIIKKI Alpha-helical proteins Cell membrane disruption; Cell apoptosis MTT/MTS assay HeLa Cervical cancer 95 % Cytotoxicity at 4µM approx.
dbacp06081 Short α-helical peptide GIIKKIIKKIIKKIIKKI Alpha-helical proteins Cell membrane disruption; Cell apoptosis MTT/MTS assay HeLa Cervical cancer 80% Cytotoxicity at 4µM
dbacp06082 Short α-helical peptide GIIKKIIKKI Alpha-helical proteins Cell membrane disruption; Cell apoptosis MTT/MTS assay HL-60 Leukemia cancer 100% Cytotoxicity at 4µM approx.
dbacp06083 Short α-helical peptide GIIKKIIKKIIKKI Alpha-helical proteins Cell membrane disruption; Cell apoptosis MTT/MTS assay HL-60 Leukemia cancer 90% Cytotoxicity at 4µM approx.
dbacp06084 Short α-helical peptide GIIKKIIKKIIKKIIKKI Alpha-helical proteins Cell membrane disruption; Cell apoptosis MTT/MTS assay HL-60 Leukemia cancer 70% Cytotoxicity at 5µM approx.
dbacp06169 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer Not found
dbacp06170 SVS-1 KVKVKVKVpPTKVKVKVK Bovine lactoferrin (Lf-B) Disruption of cell membranes MTT/MTS assay KB Oral cancer Not found
dbacp06171 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : 8.1 ± 0.8 µM
dbacp06172 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MDA-MB-436 Breast cancer IC50 : 5.6 ± 0.5 µM
dbacp06173 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay A-549 Lung cancer IC50 : >100 µM
dbacp06174 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay KB Oral cancer IC50 : >100 µM
dbacp06175 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : >100 µM
dbacp06176 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MDA-MB-436 Breast cancer IC50 : >100 µM
dbacp06177 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Calu-6 Lung cancer 35% survival rate at 10 µM
dbacp06178 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Calu-6 Lung cancer 0% survival rate at 100 µM
dbacp06179 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Jurkat Blood cancer ~60% survival rate at 10 µM
dbacp06180 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay Jurkat Blood cancer 0% survival rate at 100 µM
dbacp06181 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay SNU-601 Gastric cancer ~20% survival rate at 10 µM
dbacp06182 Synthetic peptide KWKKLLKKPPPLLKKLLKKL Synthetic peptide Not specified MTT/MTS assay SNU-601 Gastric cancer 0% survival rate at 100 µM
dbacp06188 T Peptide TKPRKTKPRKTKPRKTKPR Tuftsin derivative Immune regulation MTT/MTS assay HepG-2 Liver cancer 69.6% maximum inhibitory rate at 8 mg/kg
dbacp06189 T Peptide TKPRKTKPRKTKPRKTKPR Tuftsin derivative Immune regulation MTT/MTS assay HT-29 Colon cancer 70% maximum inhibitory rate at 8 mg/kg
dbacp06190 T Peptide TKPRKTKPRKTKPRKTKPR Tuftsin derivative Immune regulation MTT/MTS assay BGC-823 Gastric cancer 67.2% maximum inhibitory rate at 8 mg/kg
dbacp06195 Tat RKKRRQRRR HIV-Tat (49-57) Apoptosis inducing MTT/MTS assay HCT-116 Colon cancer ~10% cytotoxicity at 100 µM
dbacp06196 Tat (47-57) YGRKKRRQRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 1 µM 90 - 100% viablity
dbacp06197 Tat (47-57) YGRKKRRQRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 10 µM 80% viablity
dbacp06198 Tat (47-57) YGRKKRRQRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 100 µM 60% viablity
dbacp06199 Tat-a5 KAQIRAMECNILGRKKRRQRRR HIV-Tat (49-57) Apoptosis inducing MTT/MTS assay HCT-116 Colon cancer ~80% cytotoxicity at 100 µM
dbacp06222 Tempoprin-1CEa FVDLKKIANIINSIF Chinese brown frog Cell membrane disruption MTT/MTS assay Bcap-37 Breast cancer 70% Cell viability at 20 µM
dbacp06223 Tempoprin-1CEa FVDLKKIANIINSIF Chinese brown frog Cell membrane disruption MTT/MTS assay Bcap-37 Breast cancer 45% Cell viability at 30 µM
dbacp06224 Tempoprin-1CEa FVDLKKIANIINSIF Chinese brown frog Cell membrane disruption MTT/MTS assay Bcap-37 Breast cancer 30 % Cell viability at 40 µM
dbacp06226 Temporin A FLPLIGRVLSGIL Common frog Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis MTT/MTS assay U-943 Lymphoma cancer IC50 : 80-90 µg/ml
dbacp06227 Temporin A FLPLIGRVLSGIL Common frog Cell membrane disintegration MTT/MTS assay U-937 Lymphoma cancer 15% cytotoxicity at 0.5 µg/ml
dbacp06228 Temporin A FLPLIGRVLSGIL European common frog Cell membrane disintegration MTT/MTS assay U-937 Lymphoma cancer 15% cytotoxicity at 0.5 µg/ml
dbacp06230 Temporin L FVQWFSKFLGRIL European common frog Cell membrane disintegration MTT/MTS assay U-938 Lymphoma cancer 15% cytotoxicity at 0.5 µg/ml
dbacp06231 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption MTT/MTS assay MDA-MB-231 Breast cancer 22% cell viability at 40 µM
dbacp06233 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption MTT/MTS assay MCF-7 Breast cancer 61% cell viability at 40 µM
dbacp06235 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption MTT/MTS assay MDA-MB-231 Breast cancer MIC : 40 µM
dbacp06237 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption MTT/MTS assay MCF-7 Breast cancer MIC : 40 µM
dbacp06242 Temporin-1RNa ILPIRSLIKKLL The black-spotted frog, Northeastern China, Asia Disruption of membrane Cytotoxicity assay, MTT/MTS assay MCF 7 Breast cancer IC50 : 23.4 ± 5.2 µM
dbacp06243 Temporin-1RNa ILPIRSLIKKLL The black-spotted frog, Northeastern China, Asia Disruption of membrane Cytotoxicity assay, MTT/MTS assay HeLa Cervical carcinoma IC50 : 24.5 ± 3.8 µM
dbacp06244 Temporin-1RNb FLPLKKLRFGLL The black-spotted frog, Northeastern China, Asia Disruption of membrane Cytotoxicity assay, MTT/MTS assay MCF 7 Breast cancer IC50 : 11.4 ± 2.3 µM
dbacp06245 Temporin-1RNb FLPLKKLRFGLL The black-spotted frog, Northeastern China, Asia Disruption of membrane Cytotoxicity assay, MTT/MTS assay HeLa Cervical carcinoma IC50 : 12.8 ± 8.6 µM
dbacp06248 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay SW-1116 Colorectal cancer 57.62 inhibition ratio at 50 µg/ml
dbacp06249 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay SMMC-7721 Liver cancer 52.77 inhibition ratio at 50 µg/ml
dbacp06250 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer 52.32 inhibition ratio at 50 µg/ml
dbacp06251 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay HepG-2 Liver cancer 50.90 inhibition ratio at 50 µg/ml
dbacp06252 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay BGC-823 Gastric cancer 48.19 inhibition ratio at 50 µg/ml
dbacp06253 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay A-549 Lung cancer 45.62 inhibition ratio at 50 µg/ml
dbacp06254 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay HL7702 Liver cancer 37.22 inhibition ratio at 50 µg/ml
dbacp06255 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay HEK-293T Renal cancer 30.82 inhibition ratio at 50 µg/ml
dbacp06257 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay SW-1116 Colorectal cancer 62.73 inhibition ratio at 50 µg/ml
dbacp06258 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay SMMC-7721 Liver cancer 59.37 inhibition ratio at 50 µg/ml
dbacp06259 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer 56.81 inhibition ratio at 50 µg/ml
dbacp06260 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay HepG-2 Liver cancer 55.98 inhibition ratio at 50 µg/ml
dbacp06261 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay BGC-823 Gastric cancer 50.85 inhibition ratio at 50 µg/ml
dbacp06262 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay A-549 Lung cancer 50.64 inhibition ratio at 50 µg/ml
dbacp06263 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay HL7702 Liver cancer 37.00 inhibition ratio at 50 µg/ml
dbacp06264 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay HEK-293T Renal cancer 30.90 inhibition ratio at 50 µg/ml
dbacp06265 Temporin-Las LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay MEC Breast cancer 24.15 inhibition ratio at 50 µg/ml
dbacp06266 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay MEC Breast cancer 27.99 inhibition ratio at 50 µg/ml
dbacp06293 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 0.96 nM
dbacp06294 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay DU Prostate cancer IC50 : 1.30 nM
dbacp06295 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 0.64 nM
dbacp06346 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 1.70 nM
dbacp06347 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay DU Prostate cancer IC50 : 3.88 nM
dbacp06348 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 3.00 nM
dbacp06349 Tritrpticin VRRFPWWWPFLRR Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay A-549 Lung cancer IC50 : > 200 µg/ml
dbacp06350 Tritrpticin VRRFPWWWPFLRR Derivative of tritrpticin Cell membrane disintegration MTT/MTS assay MDA-MB-361 Breast cancer IC50 : 142 µg/ml
dbacp06358 TsAP-1 FLSLIPSLVGGSISAFK Venom-derived cDNAlibrary of the Brazilian yellow scorpion Not specified MTT/MTS assay HI-57 Lung cancer IC50 : 55.9 µM
dbacp06359 TsAP-1 FLSLIPSLVGGSISAFK Venom-derived cDNAlibrary of the Brazilian yellow scorpion Not specified MTT/MTS assay H-838 Lung cancer IC50 : 52.5 µM
dbacp06360 TsAP-2 FLGMIPGLIGGLISAFK Venom-derived cDNAlibrary of the Brazilian yellow scorpion Not specified MTT/MTS assay HI-57 Lung cancer IC50 : 4.1 µM
dbacp06361 TsAP-2 FLGMIPGLIGGLISAFK Venom-derived cDNAlibrary of the Brazilian yellow scorpion Not specified MTT/MTS assay H-838 Lung cancer IC50 : 11.0 µM
dbacp06362 TsAP-2 FLGMIPGLIGGLISAFK Venom-derived cDNAlibrary of the Brazilian yellow scorpion Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 6.4 µM
dbacp06363 TsAP-2 FLGMIPGLIGGLISAFK Venom-derived cDNAlibrary of the Brazilian yellow scorpion Not specified MTT/MTS assay PC-3 Prostate cancer IC50 : 13.3 µM
dbacp06364 TsAP-2 FLGMIPGLIGGLISAFK Venom-derived cDNAlibrary of the Brazilian yellow scorpion Not specified MTT/MTS assay U251-MG Brain tumor IC50 : 15.4 µM
dbacp06365 TsAP-2 FLGMIPGLIGGLISAFK Venom, the Brazilian yellow scorpion, South America Not specified MTT/MTS assay U251-MG Human squamous carcinoma IC50 : 15.4 µM
dbacp06366 TsAP-2 FLGMIPGLIGGLISAFK Venom, the Brazilian yellow scorpion, South America Not specified MTT/MTS assay NCI-H157 Human squamous carcinoma IC50 : 4.1 µM
dbacp06367 TsAP-2 FLGMIPGLIGGLISAFK Venom, the Brazilian yellow scorpion, South America Not specified MTT/MTS assay NCI-H838 Human squamous carcinoma IC50 : 11.0 µM
dbacp06368 TsAP-S1 FLSLIPKLVKKIIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay HI-57 Lung cancer IC50 : 1.5 µM
dbacp06369 TsAP-S1 FLSLIPKLVKKIIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay H-838 Lung cancer IC50 : 1.6 µM
dbacp06370 TsAP-S1 FLSLIPKLVKKIIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 1.8 µM
dbacp06371 TsAP-S1 FLSLIPKLVKKIIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay PC-3 Prostate cancer IC50 : 2.1 µM
dbacp06372 TsAP-S1 FLSLIPKLVKKIIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay U251-MG Brain tumor IC50 : 2.9 µM
dbacp06373 TsAP-S1 FLSLIPKLVKKIIKAFK The iNot foundctive natural peptide TsAP-1 was made active by increasing 4 lysines and one leucine, template-based design Not specified MTT/MTS assay U251-MG Human squamous carcinoma IC50 : 0.83 - 2.0 µM
dbacp06374 TsAP-S1 FLSLIPKLVKKIIKAFK The iNot foundctive natural peptide TsAP-1 was made active by increasing 4 lysines and one leucine, template-based design Not specified MTT/MTS assay NCI-H157 Human squamous carcinoma IC50 : 55.9 µM
dbacp06375 TsAP-S1 FLSLIPKLVKKIIKAFK The iNot foundctive natural peptide TsAP-1 was made active by increasing 4 lysines and one leucine, template-based design Not specified MTT/MTS assay NCI-H838 Human squamous carcinoma IC50 : 52.5µM
dbacp06376 TsAP-S2 FLGMIPKLIKKLIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay HI-57 Lung cancer IC50 : 0.83 µM
dbacp06377 TsAP-S2 FLGMIPKLIKKLIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay H-838 Lung cancer IC50 : 1.6 µM
dbacp06378 TsAP-S2 FLGMIPKLIKKLIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 1.8 µM
dbacp06379 TsAP-S2 FLGMIPKLIKKLIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay PC-3 Prostate cancer IC50 : 1.6 µM
dbacp06380 TsAP-S2 FLGMIPKLIKKLIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay U251-MG Brain tumor IC50 : 2.0 µM
dbacp06404 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 49.4% Cytotoxic at 0.1 µg/ml
dbacp06405 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 51.2% Cytotoxic at 1 µg/ml
dbacp06406 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 53.0% Cytotoxic at 10 µg/ml
dbacp06407 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay B16-F10 Skin cancer 61.2% Cytotoxic at 100 µg/ml
dbacp06408 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 39.0% Cytotoxic at 0.1 µg/ml
dbacp06409 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 20.8% Cytotoxic at 1 µg/ml
dbacp06410 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 33.8% Cytotoxic at 10 µg/ml
dbacp06411 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 35.6% Cytotoxic at 100 µg/ml
dbacp06415 U3 NGSIPATWASL Date palm Cell proliferation inhibition MTT/MTS assay T47D Breast cancer IC50 : 434.7 – 616.5 μM
dbacp06416 U3 NGSIPATWASL Date palm Cell proliferation inhibition MTT/MTS assay MCF-7 Breast cancer IC50 : 555 μM
dbacp06417 U3 NGSIPATWASL Date palm Cell proliferation inhibition MTT/MTS assay Hep G2 Liver cancer IC50 : 561 μM
dbacp06418 U7 NCSIHGDIPAY Date palm Cell proliferation inhibition MTT/MTS assay T47D Breast cancer IC50 : 485.3–702.8 μM
dbacp06419 U7 NCSIHGDIPAY Date palm Cell proliferation inhibition MTT/MTS assay MCF-7 Breast cancer IC50 : 554 μM
dbacp06420 U7 NCSIHGDIPAY Date palm Cell proliferation inhibition MTT/MTS assay Hep G2 Liver cancer IC50 : 523 μM
dbacp06534 wtmda-7/IL-24 MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL Not found Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer Cell viability (% of control):0.5 at concentration 7 µg/ml
dbacp06535 wtmda-7/IL-24 MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL Not found Apoptosis inducing MTT/MTS assay Ket-3 Tumor Cell viability (% of control): 0.5 at concentration 8 µg/ml
dbacp06548 Z1 KAAKKWAKAAKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : > 211 µM
dbacp06549 Z1 KAAKKWAKAAKKWAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 186 µM
dbacp06550 Z1 KAAKKWAKAAKKWAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : > 211 µM
dbacp06551 Z10 AAKKWAKAKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : > 211 µM
dbacp06552 Z10 AAKKWAKAKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : > 211 µM
dbacp06553 Z10 AAKKWAKAKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : > 211 µM
dbacp06554 Z2 KAAKKWAKAWKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : > 211 µM
dbacp06555 Z2 KAAKKWAKAWKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 173 µM
dbacp06556 Z2 KAAKKWAKAWKKAAKAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : > 211 µM
dbacp06567 Z3 KAAKKAWKAWKKAAKAAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : >211 µM
dbacp06568 Z3 KAAKKAWKAWKKAAKAAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 128 µM
dbacp06569 Z3 KAAKKAWKAWKKAAKAAWKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : >211 µM
dbacp06570 Z4 KAAKKAWKAAKKAAKWWKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 155 µM
dbacp06571 Z4 KAAKKAWKAAKKAAKWWKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 68 µM
dbacp06572 Z4 KAAKKAWKAAKKAAKWWKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 173 µM
dbacp06583 Z5 KAAKKAWKWAKKAAKWAKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 42 µM
dbacp06584 Z5 KAAKKAWKWAKKAAKWAKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 28 µM
dbacp06585 Z5 KAAKKAWKWAKKAAKWAKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 67 µM
dbacp06586 Z6 KWWKKAAKAAKKAAKAAKKWA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 17 µM
dbacp06587 Z6 KWWKKAAKAAKKAAKAAKKWA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 16 µM
dbacp06588 Z6 KWWKKAAKAAKKAAKAAKKWA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 31 µM
dbacp06589 Z7 KAAKKAWKAAKKAWKAAKKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 15 µM
dbacp06590 Z7 KAAKKAWKAAKKAWKAAKKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 15 µM
dbacp06591 Z7 KAAKKAWKAAKKAWKAAKKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 21 µM
dbacp06592 Z8 AWKKWAKAWKWAKAKWWAKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 19 µM
dbacp06593 Z8 AWKKWAKAWKWAKAKWWAKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 14 µM
dbacp06594 Z8 AWKKWAKAWKWAKAKWWAKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 23 µM
dbacp06595 Z9 AAWKWAWAKKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay Meth A Skin cancer EC50 : 9 µM
dbacp06596 Z9 AAWKWAWAKKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay MT-1 Breast cancer EC50 : 16 µM
dbacp06597 Z9 AAWKWAWAKKWAKAKKWAKAA Synthetic Disruption of cell membrane MTT/MTS assay HT-29 Colon cancer EC50 : 13 µM
dbacp06605 αs1-casein f(90_95) RYLGYL Bovine milk Regulation of immune response; Apoptosis inducing MTT/MTS assay AZ-97 Colon cancer Inhibition at 12 - 15 g/l
dbacp06606 β-Casomorphins 5 f(60_64) YPFPG Bovine milk Regulation of immune response; Apoptosis inducing MTT/MTS assay AZ-97 Colon cancer Inhibition at 9 - 11 g/l
dbacp06777 BK-1 rRP-Hyp-G-Thi-S-Apc-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06778 BK-2 rRP-Hyp-G-Thi-S-f-Apc-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06779 BK-3 Aaa-rRP-Hyp-G-Thi-S-Acc-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06780 BK-4 Aaa-rRP-Hyp-G-Thi-S-f-Acc-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06781 BK-5 rRP-Hyp-G-Thi-S-f-(L)Pip-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06782 BK-6 Aaa-rRP-Hyp-G-Thi-S-(D)Pip-(L)Pip-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06783 BK-7 rRP-Hyp-G-Thi-S-(D)Pip-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06784 BK-8 Aaa-rRP-Hyp-G-Thi-S-(D)Pip-Thi-R Synthetic analogue of Bradykinin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06785 NT-9 RRPYIL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06786 NT-10 RRPAIL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06787 NT-11 RRPYAL Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06788 NT-12 PEGRKPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06789 NT-12 PEGKRPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06790 NT-12 PEGKKPY-Tle-L Synthetic analogue of Neurotensin Not available MTS assay HCT-116 Colorectal Cancer Not Available
dbacp06842 Api8-NH2 UGLUGGLZGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 > 20 µM
dbacp06843 Leu4-NH2 UGLLGGLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 > 20 µM
dbacp06844 K2569-Lol UKLUKKLUKI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 = 12 µM
dbacp06845 K259-NH2 UKLUKGLUKI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =13 µM
dbacp06846 K259-Lol UKLUKGLUKI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =10 µM
dbacp06847 K25-Lol UKLUKGLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =9 µM
dbacp06848 K56-Lol UGLUKKLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =12 µM
dbacp06849 K6-NH2 UGLUGKLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 =8 µM
dbacp06850 K2-NH2 UKLUGGLUGI Trichogin GA Not available MTS assay MDA-MB-231 Breast Cancer IC50 = 9 µM
dbacp06910 mtp1 DGDWDAWTRETS Synthetic Disrupts transcription MTS assay MDA-MB-231 Breast Cancer 33.6% decrease in cell viability at 10 μM
dbacp06911 mtp1 DGDWDAWTRETS Synthetic Disrupts transcription MTS assay HeLa Cervical Cancer 30.2 % decrease in cell viability at 10 μM
dbacp06912 mtp1 DGDWDAWTRETS Synthetic Disrupts transcription MTS assay A-549 Lung Cancer 17.4% decrease in cell viability at 10 μM
dbacp07102 rScyreprocin MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH Recombinant product of Scyreprocin Membrane disruption triggers ROS-mediated apoptosis MTS assay H-460 Lung Cancer IC50 = 6.27 µM
dbacp07103 rScyreprocin MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH Recombinant product of Scyreprocin Membrane disruption triggers ROS-mediated apoptosis MTS assay HepG-2 Liver Cancer IC50 = 441.01 µM
dbacp07104 rScyreprocin MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH Recombinant product of Scyreprocin Membrane disruption triggers ROS-mediated apoptosis MTS assay T-24 Urinary Bladder Cancer IC50 = 1.94 x 105 µM
dbacp07105 rScyreprocin MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH Recombinant product of Scyreprocin Membrane disruption triggers ROS-mediated apoptosis MTS assay DU-145 Prostate cancer IC50 = 1158.30 µM
dbacp07106 rScyreprocin MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH Recombinant product of Scyreprocin Membrane disruption triggers ROS-mediated apoptosis MTS assay HeLa Cervical cancer IC50 = 3.34 x 104 µM
dbacp07322 PCC-1 KKRKKKAFALKFVVDLI Poecilocoris lewisi Sp1 suppression, apoptosis, cell-cycle arrest MTS assay SK-Mel-28 Skin Cancer IC50 = 50.8 µM
dbacp07323 PCC-1 KKRKKKAFALKFVVDLI Poecilocoris lewisi Sp1 suppression, apoptosis, cell-cycle arrest MTS assay G361 Skin Cancer IC50 = 57.8 µM
dbacp07339 D-melittin gigavlkvlttglpaliswikrkrqqc Synthetic pH-triggered release, membrane lysis, immunogenic death MTS assay A-549 Lung Cancer IC50 = 4.5 µM
dbacp07340 D-melittin gigavlkvlttglpaliswikrkrqqc Synthetic pH-triggered release, membrane lysis, immunogenic death MTS assay CT-26 Colorectal Cancer IC50 = 2.2 µM
dbacp07341 D-melittin gigavlkvlttglpaliswikrkrqqc Synthetic pH-triggered release, membrane lysis, immunogenic death MTS assay MDA-MB-435 WT Breast Cancer IC50 = 3.5 µM
dbacp07342 D-melittin gigavlkvlttglpaliswikrkrqqc Synthetic pH-triggered release, membrane lysis, immunogenic death MTS assay MDA-MB-435 DOX-R Breast Cancer IC50 = 3.4 µM
dbacp07404 LvHemB1 DVNFLLHKIYGNIRY hemocyanin of Litopenaeus vannamei Mitochondrial targeting induces apoptosis MTS assay HeLa Cervical cancer 65.1% apoptotic cells at 50 μg/mL
dbacp07405 LvHemB1 DVNFLLHKIYGNIRY hemocyanin of Litopenaeus vannamei Mitochondrial targeting induces apoptosis MTS assay EC-109 Esophageal Cancer 57.1% apoptotic cells at 50 μg/mL
dbacp07406 LvHemB1 DVNFLLHKIYGNIRY hemocyanin of Litopenaeus vannamei Mitochondrial targeting induces apoptosis MTS assay HepG-2 Liver Cancer 44.2% apoptotic cells at 50 μg/mL
dbacp07407 LvHemB1 DVNFLLHKIYGNIRY hemocyanin of Litopenaeus vannamei Mitochondrial targeting induces apoptosis MTS assay EJ Bladder Cancer 89.6% apoptotic cells at 50 μg/mL
dbacp07535 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay CT-26 Colorectal Cancer ~20% cell viability at 10 μg/mL
dbacp07536 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay ID8 Colon Cancer ~60% cell viability at 10 μg/mL
dbacp07537 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay OV-2008 Ovarian Cancer ~60% cell viability at 10 μg/mL
dbacp07538 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay SK-OV-3 Ovarian Cancer ~50% cell viability at 10 μg/mL
dbacp07539 AEM-28 LRKLRKRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay CaCo-2 Colon Cancer ~70% cell viability at 10 μg/mL
dbacp07540 HM-10/10 LRKLRKRLLRLVGRQLEEFL Synthetic LPA reduction suppresses tumor growth MTS assay CT-26 Colorectal Cancer ~60% cell viability at 10 μg/mL
dbacp07541 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay CT-26 Colorectal Cancer ~30% cell viability at 10 μg/mL
dbacp07542 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay ID8 Colon Cancer ~20% cell viability at 10 μg/mL
dbacp07543 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay OV-2008 Ovarian Cancer ~40% cell viability at 10 μg/mL
dbacp07544 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay SK-OV-3 Ovarian Cancer ~30% cell viability at 10 μg/mL
dbacp07545 AEM-28–2 Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF Synthetic LPA reduction suppresses tumor growth MTS assay CaCo-2 Colon Cancer ~60% cell viability at 10 μg/mL
dbacp07578 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 125.0 ± 16.8 μM
dbacp07579 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 10.7 ± 0.2 μM
dbacp07580 R-DIM-P-LF11 FQWQRNIRKVRPRVKRINRQWQF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 20.9 ± 3.9 μM
dbacp07581 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 4.2 ± 0.2 μM
dbacp07582 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 2.5 ± 0.1 μM
dbacp07583 R-DIM-P-LF11-322 PFWRIRIRRPRRIRIRWFP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 4.7 ± 0.2 μM
dbacp07584 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 6.3 ± 0.3 μM
dbacp07585 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 < 1 ± 0.0 μM
dbacp07586 DIM-LF11-322 PFWRIRIRRPFWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 4.6 ± 0.1 μM
dbacp07587 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 2.7 ± 0.9 μM
dbacp07588 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 < 1 ± 0.0 μM
dbacp07589 R-DIM-P-LF11-215 FWRIRIRRPRRIRIRWF Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 4.6 ± 0.1 μM
dbacp07590 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 6.6 ± 0.3 μM
dbacp07591 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 3.4 ± 0.4 μM
dbacp07592 R-DIM-P-LF11-334 PWRIRIRRPRRIRIWP Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 5.0 ± 0.1 μM
dbacp07593 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 < 1 ± 0.1 μM
dbacp07594 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 < 1 ± 0.1 μM
dbacp07595 R-DIM-LF11-334-LF11-334 PWRIRIRRRRIRIRWPPWRIRIRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 3.6 ± 0.7 μM
dbacp07596 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay A-375 Skin Cancer LC50 = 4.8 ± 0.4 μM
dbacp07597 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay SBcl2 Skin Cancer LC50 = 4.7 ± 0.3 μM
dbacp07598 DIM-LF11-339 RRWFWRRRRWFWRR Synthetic Peptides target phosphatidylserine, trigger apoptosis MTS assay WM164 Skin Cancer LC50 = 3.8 ± 0.3 μM
dbacp07928 B11 RIRDAIAHGYIVDKV Litopenaeus vannamei hemocyanin-derived peptide Mitochondrial dysfunction, caspase-dependent apoptosis MTS assay HeLa Cervical Cancer Decreased cell viability by 20% at 50 μg/mL
dbacp07929 B11 RIRDAIAHGYIVDKV Litopenaeus vannamei hemocyanin-derived peptide Mitochondrial dysfunction, caspase-dependent apoptosis MTS assay HepG-2 Liver Cancer Decreased cell viability by 23% at 50 μg/mL
dbacp07930 B11 RIRDAIAHGYIVDKV Litopenaeus vannamei hemocyanin-derived peptide Mitochondrial dysfunction, caspase-dependent apoptosis MTS assay EC-109 Esophageal Cancer Decreased cell viability by 13% at 50 μg/mL
dbacp07937 Pantinin-1 GILGKLWEGFKSIV Synthetic Selective binding, membrane disruption, apoptosis MTS assay MDA-MB-231 Breast Cancer IC50 = 28.5 ± 1.0 µM
dbacp07938 Pantinin-1 GILGKLWEGFKSIV Synthetic Selective binding, membrane disruption, apoptosis MTS assay DU-145 Prostate Cancer IC50 = 47.5 ± 2.0 µM
dbacp07939 Pantinin-2 IFGAIWKGISSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay MDA-MB-231 Breast Cancer IC50 = 12.5 ± 1.0 µM
dbacp07940 Pantinin-2 IFGAIWKGISSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay DU-145 Prostate Cancer IC50 = 16.5 ± 1.0 µM
dbacp07941 Pantinin-3 FLSTIWNGIKSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay MDA-MB-231 Breast Cancer IC50 = 13.5 ± 2.0 µM
dbacp07942 Pantinin-3 FLSTIWNGIKSLL Synthetic Selective binding, membrane disruption, apoptosis MTS assay DU-145 Prostate Cancer IC50 = 17.3 ± 1.0 µM
dbacp08049 Temporin-1Ga SILPTIVSFLSKVF Synthetic Temporin-1OLa disrupts bacterial membranes MTS assay 4T1 Breast Cancer LC50 = 20 μM
dbacp08050 Temporin-CPa IPPFIKKVLTTVF Synthetic Temporin-1OLa disrupts bacterial membranes MTS assay 4T1 Breast Cancer LC50 = 80 μM
dbacp08052 Poca A GLPCAESCVFIPCTITAILGCSCRDRVCYD Pombalia calceolaria Cyclotides induce cytotoxicity, inhibit migration MTS assay MDA-MB-231 Breast Cancer IC50 = 1.8 μM
dbacp08053 Poca B GIPCAESCVFIPCVTAILGCSCKDVCYN Pombalia calceolaria Cyclotides induce cytotoxicity, inhibit migration MTS assay MDA-MB-231 Breast Cancer IC50 = 2.7 μM
dbacp08054 CyO4 GIPCGESCVWIPCISSAIGCSCKNKVCYRN Viola odorata Cyclotides induce cytotoxicity, inhibit migration MTS assay MDA-MB-231 Breast Cancer IC50 = 9.8 μM
dbacp08167 Bmattacin2 Not Available silkworm Bombyx mori Not Available MTS assay A-375 Skin Cancer IC50 = 5.23 μM
dbacp08168 Bmattacin2 Not Available silkworm Bombyx mori Not Available MTS assay HCT-116 Colorectal Cancer IC50 = 1.70 μM